ID=H0055
URL=http://www.who.int/ncd/hgn/hcprevention.htm
SIZE=287581
DATE=11/07/2002
TIME=17:00:34
DATASET=Biology
HTML=<html>
<head>
<title>primary health care approaches for prevention and control of congenital and genetic
disorders</title>
<meta name="DC.title" content="primary health care approaches for prevention and control of congenital and genetic
disorders">

<meta name="Microsoft Border" content="none">
<meta name="DC.publisher" content="World Health Organization">
<meta name="DC.rights" content="http://www.who.int/home/copyright">
<meta name="DC.format" content="text/html">
<meta name="who.pubdate" content="Wed Jun 19 08:37:12 2002">
<meta name="who.pubby" content="kerneng@who.int">

</head>
<body topmargin="0" leftmargin="0" vlink="#008080" alink="#FF0000">
<table border="0" width="640" style="border: ">
  <tr>
    <td width="640"><table height="1" width="631">
      <tr>
        <td rowSpan="2" vAlign="top" width="120"><a href="/"><img
        alt="World Health Organization" border="0" src="../images/whologo.jpg" width="120" height="80"></a></td>
        <td vAlign="top" width="500"><a href="/"><img
        alt="World Health Organization" border="0" src="../images/top_line.gif" width="500" height="12"></a></td>
      </tr>
      <tr>
        <td vAlign="top" width="500"><p align="right"><img src="../images/hgn.gif"
        alt="hgn.gif (8550 bytes)" width="500" height="70"></td>
      </tr>
      <tr>
        <td colSpan="2" vAlign="top" width="620"><img src="../images/blue.gif"
        alt="blue.gif (943 bytes)" align="right" width="620" height="12"></td>
      </tr>
</TBODY>
    </table>
    </td>
  </tr>
  <tr>
    <td width="620"><p align="right"><font face="Arial,Helvetica,Sans Serif" size="1">Last update:18 Jun 2002</font></td>
  </tr>
  <tr>
    <td width="620"><font face="Arial,Helvetica,Sans Serif" size="1"><p align="center"></font><font size="2"><strong>|
    <a href="/m/healthtopics-a-z/en/index.html">Health topics</a> |&nbsp; <a
    href="/">WHO home</a> | <a
    href="/site-search/data-who-hq-live/search.shtml">Search</a> | <a
    href="../ncd_sitemap.htm">Site map</a> | <a href="../contact_us.htm">Contact us</a> |</strong></font></td>
  </tr>
  <tr>
    <td width="620"><hr>
    </td>
  </tr>
  <tr>
    <td width="620"><font size="2"><p align="right"><a href="/">WHO Home </a>-&gt;
    <a href="index.htm">Human genetics</a> -&gt; <a href="publications.htm">Human genetics
    publications</a> -&gt; Primary health care approaches for prevention and control of
    congenital and genetic disorders<br>
    </font><br>
    </td>
  </tr>
  <tr>
    <td width="620"><div align="center"><center><table border="0" cellPadding="3"
    cellSpacing="0" width="615">
<TBODY>
      <tr>
        <td vAlign="top" width="500" height="1"><font size="2"><i>Document reference</i><span
        lang="EN-GB" style="font-size:9.0pt;mso-bidi-font-size:10.0pt">: <em>WHO/HGN/WG/00.1,
        &nbsp; </span><!--[if supportFields]><span class=manual><span lang=EN-GB
style='font-size:9.0pt;mso-bidi-font-size:10.0pt'><span style='mso-element:
field-begin'></span>PRIVATE </span></span><![endif]--><span lang="EN-GB" style="font-size:9.0pt;mso-bidi-font-size:10.0pt">ENGLISH
        ONLY, </span><span lang="EN-GB"
        style="font-size:9.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times";mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA;layout-grid-mode:line">Distr.:<span
        style="mso-spacerun: yes">&nbsp; </span>GENERAL</span></em></font><i><font SIZE="-1"> </font></i><p>&nbsp;</p>
        <p align="center"><strong>&nbsp;<font size="3" color="#8000FF">&nbsp;&nbsp;</font><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Arial;mso-bidi-font-family:"Times New Roman";font-variant:
small-caps"><font-size="3">Primary
        health care approaches for prevention an control of congenital and genetic disorders</span></strong></p>
        <p class="MsoHeading9" align="center"><font face="Arial Black"><em><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times" font-style:normal">Report
        of a WHO meeting<o:p></span></em></font></p>
        <i style="mso-bidi-font-style:normal"><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times"mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman" mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA; layout-grid-mode:line"><b
        style="mso-bidi-font-weight:normal"><p align="center"></b><u>Cairo, Egypt, 6-8 Decembre
        1999</u></span></i></td>
        <td vAlign="top" width="146" height="1" bgcolor="#eaeaf2"><table>
          <tr>
            <th bgColor="#000080"><font face="Arial,Helvetica,Sans Serif" size="2" color="#FFFF00"><strong>Human genetics
            shortcut</strong></font></th>
          </tr>
          <tr>
            <td><a href="hgn_news.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>News</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="publications.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Publications</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="databases.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Databases</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="hgn_events.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Events</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="country_profiles.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Country
            profiles</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="glopartners.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Global
            partners</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="collcentres.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Collaborating
            centres</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="relatedsites.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Related
            sites</em></strong></font></a></td>
          </tr>
        </table>
        </td>
      </tr>
      <tr>
        <td colSpan="2" vAlign="top" width="620" height="1"><table border="0" width="100%">
          <tr>
            <td width="100%"><table border="1" cellspacing="0" cellpadding="0"
            style="margin-left:-1.7pt;
 border-collapse:collapse;mso-table-layout-alt:fixed;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"
            width="593" bordercolor="#008080" bordercolorlight="#008080" bordercolordark="#008080">
              <tr>
                <td width="300" valign="top" style="width:240.95pt;padding:0cm 5.4pt 0cm 5.4pt"
                align="center" bordercolor="#008080" bordercolorlight="#008080" bordercolordark="#008080"><p
                class="MsoNormal" style="margin-top:4.5pt;mso-hyphenate:none;tab-stops:-36.0pt"><span
                lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt">This document is not a
                formal publication of the World Health Organization (WHO), and all rights are reserved by
                the Organization.<span style="mso-spacerun: yes">&nbsp; </span>The document may, however,
                be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not
                for sale nor for use in conjunction with commercial purposes.<o:p></o:p>&nbsp;<o:p></o:p></span></p>
                <p class="MsoNormal" style="margin-bottom:2.7pt;mso-hyphenate:none;tab-stops:
  -36.0pt"><span
                lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt">The views expressed in
                documents by named authors are solely the responsibility of those authors.<o:p></o:p></span></td>
                <td width="300" valign="top" style="width:240.95pt;padding:0cm 5.4pt 0cm 5.4pt"
                align="center"><p class="MsoNormal"
                style="margin-top:4.5pt;mso-hyphenate:none;tab-stops:-36.0pt"><span lang="FR"
                style="font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-ansi-language:
  FR">Ce document
                n'est pas une publication officielle de l'Organisation mondiale de la Santé (OMS) et tous
                les droits y afférents sont réservés par l'Organisation.<span style="mso-spacerun: yes">&nbsp;
                </span>S'il peut être commenté, résumé, reproduit ou traduit, partiellement ou en
                totalité, il ne saurait cependant l'être pour la vente ou à des fins commerciales.<o:p></o:p></span></p>
                <p class="MsoNormal" style="margin-bottom:2.7pt;mso-hyphenate:none;tab-stops:
  -36.0pt"><span
                lang="FR" style="font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-ansi-language:FR">Les
                opinions exprimées dans les documents par des auteurs cités nommément n'engagent que
                lesdits auteurs.<o:p></o:p></span></td>
              </tr>
            </table>
            </td>
          </tr>
        </table>
        <p align="center" style="text-align:center"><font size="3"><span lang="EN-US">Table of
        contents</span></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><span lang="EN-US"><a
        href="#1. &nbsp; Introduction">1. Introduction</a><o:p></o:p></span></font></p>
        <p style="tab-stops:right dotted 453.0pt"><span lang="EN-US"><font size="3"><a
        href="#2.&nbsp;&nbsp; Global epidemiology and health burden of congenital disorders">2.
        Global epidemiology and health burden of congenital disorders<span lang="EN-US"><o:p></o:p></span></a></font></p>
        <p><span lang="EN-US"><font size="3"><a href="#2.1&nbsp; Dilemmas for health services">2.1&nbsp;
        Dilemmas for health services<span lang="EN-US"><o:p></o:p></span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><span lang="EN-US"><font size="3"><a
        href="#2.2&nbsp; The burden for families">2.2&nbsp; The burden for families<span
        lang="EN-US"><o:p></o:p></span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><span lang="EN-US"><font size="3"><a
        href="#2.3&nbsp; Identifying priorities and key conditions for intervention">2.3&nbsp;
        Identifying priorities and key conditions for intervention<span lang="EN-US"><o:p></o:p></span></a></font></p>
        <p style="tab-stops:24.0pt right dotted 453.0pt"><span lang="EN-US"><font size="3"><a
        href="#3.&nbsp; Basic reproductive health approaches">3. Basic reproductive health
        approaches <span lang="EN-US"><o:p></o:p></span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><span lang="EN-US"><font size="3"><a
        href="#3.1&nbsp; Family planning">3.1&nbsp; Family planning<span lang="EN-US"><o:p></o:p></span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#3.2 &nbsp; Optimizing women's diet"><span lang="EN-US">3.2&nbsp; Optimising
        women's diet<o:p></o:p></span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#3.3&nbsp; Managing maternal health problems"><span lang="EN-US">3.3&nbsp; Managing
        maternal health problems</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#3.4&nbsp; Avoiding maternal infections"><span lang="EN-US">3.4&nbsp; Avoiding
        maternal infections</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#3.5&nbsp; Implementation of basic reproductive health approaches"><span
        lang="EN-US">3.5&nbsp; Implementation of basic reproductive health approaches</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.&nbsp; Screening for increased risk of congenital disorders"><span lang="EN-US">4.
        Screening for increased risk of congenital disorders </span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.1&nbsp; General ethical principles of genetic population screening"><span
        lang="EN-US">4.1&nbsp; General ethical principles of genetic population screening</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.2&nbsp; Antenatal ultrasound screening for congenital malformations"><span
        lang="EN-US">4.2&nbsp; Antenatal ultrasound screening for congenital malformations</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.3&nbsp; Antenatal screening for chromosomal disorders"><span lang="EN-US">4.3&nbsp;
        Antenatal screening for chromosomal disorders</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.4&nbsp; Identifying increased risk of inherited disorders"><span lang="EN-US">4.4&nbsp;
        Identifying increased risk of inherited disorders</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.5&nbsp; Genetic counselling and consanguineous marriage"><span lang="EN-US">4.5&nbsp;
        Genetic counselling and consanguineous marriage</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.6&nbsp; Avoiding morbidity and mortality due to neonatal jaundice"><span
        lang="EN-US">4.6&nbsp; Avoiding morbidity and mortality due to neonatal jaundice</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.7 &nbsp; Neonatal screening"><span lang="EN-US">4.7&nbsp; Neonatal screening</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.8 &nbsp; The timing of population screening"><span lang="EN-US">4.8&nbsp; The
        timing of population screening</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#4.9&nbsp; Education for health workers, and information for the public"><span
        lang="EN-US">4.9&nbsp; Education for health workers, and information for the public</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#5. &nbsp; The WHO initiative"><span lang="EN-US">5. The WHO initiative</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#5.1 &nbsp; Formation of a national task force"><span lang="EN-US">5.1
        &nbsp;Formation of a national task force</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#5.2 &nbsp; Development of a national plan"><span lang="EN-US">5.2&nbsp; Development
        of a national plan</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#5.3 &nbsp; The baseline epidemiological study (the WHO mother and baby study)"><span
        lang="EN-US">5.3&nbsp; The baseline epidemiological study (the WHO mother and baby study)</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#5.4 &nbsp; The intervention study (demonstration project)"><span lang="EN-US">5.4&nbsp;
        The intervention study (demonstration project)</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a
        href="#6. &nbsp; The role of WHO"><span lang="EN-US">6. The role of WHO</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a href="#List of Participants"><span
        lang="EN-US">List of Participants</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a href="#References"><span
        lang="EN-US">References</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a href="#Annex 1"><span
        lang="EN-US">Annex 1 Prevalence of genetic and congenital disorders in populations of
        European origin, to age 12</span></a></font></p>
        <p style="tab-stops:right dotted 453.0pt"><font size="3"><a href="#Annex 2">Annex 2 <span
        lang="EN-US">Options for best possible care for common congenital disorders and birth
        defects</span></a></font></p>
        <p><font size="3"><span lang="EN-US">Attachment I:&nbsp; WHO initiative on the prevention
        and control of congenital and genetic<br>
        disorders in developing countries:&nbsp; Baseline epidemiological study, draft protocol
        and data collection forms</span></font></p>
        <p><font size="3"><span lang="EN-US">Attachment II: &nbsp; WHO initiative on the
        prevention and control of congenital and genetic<br>
        disorders in developing countries:&nbsp; Baseline epidemiological study, draft manual of
        operations </span></font></p>
        <p><font size="3"><span lang="EN-US">&nbsp;<o:p></o:p></span></font></p>
        <p style="margin-bottom:6.0pt"></span></span></span></span></span><strong><font size="3">Executive
        summary<o:p></o:p></font></strong><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"></p>
        <p style="margin-bottom:6.0pt"><font size="3">As a result of the global fall in infant
        mortality and birth rate, the focus of health policy development <br>
        is shifting from acute problems towards management of chronic disease and disability, and
        from vertical programmes towards integrated primary health care systems. This change is
        particularly marked in the area of reproductive and child health, because an increasing
        proportion of infants born with potentially disabling conditions, who would previously
        have died undiagnosed, now survive and require medical and supportive interventions. The
        health burden of congenital disorders can be greatly reduced by deploying approaches for
        primary prevention, cure when feasible (e.g. paediatric surgery), supportive management
        when cure is not feasible, and availability of prenatal diagnosis and selective abortion,
        and in many developed countries infant mortality is now lower than the birth prevalence of
        potentially lethal congenital disorders.</font></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><font
        size="3"><span lang="EN-US">However, no comprehensive model of these interventions is
        available. Services in developed countries have grown up in an ad hoc manner, and are not
        perceived as components of a single discipline. The time has come to develop systematic
        scientific approaches for the control of congenital disorders, packages of care for
        implementation in reproductive and primary health care services, and appropriate training
        programmes.</span></font></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><font
        size="3"><span lang="EN-US">In December 1999 a group of WHO advisors met in Cairo at the
        WHO Meeting on Public Health Approaches for the Control of Genetically Determined
        Disorders and Birth Defects in Primary&nbsp; Health Care &nbsp;to review the global
        epidemiology of congenital and genetic disorders, identify evidence-based interventions
        that are effective in reducing health burden, and recommend approaches that are as simple
        as possible and which can be implemented in primary health care and provide a basis for
        further service development. It was concluded that the potential burden of congenital
        disorders is at least as great in developing as in developed countries, and recommended <br>
        a global initiative combining prevention, services for diagnosis and best possible patient
        care.</span></font></span></span></span></span></span></span></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><font
        size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US">Implementation of basic reproductive
        health approaches, including accessible family planning, a diet adequate in folate,
        iodine, and iron, prevention and management of maternal infections (including HIV,
        rubella, syphilis and toxoplasma) and avoidance of excess alcohol and smoking, can reduce <br>
        the birth prevalence of infants with serious congenital disorders to a baseline level.
        Further reduction depends on population screening programmes aiming to identify
        individuals at increased risk of <br>
        having children with specific disorders. Approaches include ultrasound scanning for
        congenital malformations, offering chromosome studies to older mothers, screening for
        genetic causes of neonatal jaundice and for carriers of thalassaemias and sickle cell
        disorders, and neonatal screening using clinical and biochemical methods.</span></span></span></span></span></span></span></font></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><font size="3"><span lang="EN-US">However, country differences in
        epidemiology, demographic factors, organisation of health systems, priorities, and
        available resources mean that no standard set of interventions can be recommended for
        universal application. A long-term programme including substantial research and
        development is required. The proposed WHO initiative therefore consists of a programme of
        work designed to support an organised approach to the control of congenital and genetic
        disorders in any country. It calls for formation of a national task force and development
        of a country plan, an epidemiological study to support planning and develop systems for
        education and audit, and a demonstration project followed by national implementation. </span></font></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><font
        size="3"><span lang="EN-US">A corresponding programme of work is needed at the WHO level.
        This should be developed in a collaboration of selected experts, relevant WHO programmes,
        and country representatives, in a long-term working relationship. </span></font></p>
        <p
        style="margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:0cm;margin-bottom:.0001pt"><font
        size="3"><span lang="EN-US">The approach is recommended for consideration to all
        countries. Implementation of a collaborative international study with WHO technical
        support is foreseen for selected countries.</span></font></p>
        <span lang="EN-US"><p></span>&nbsp;</p>
        <p></span></span></span></span></span><strong><font size="3">Notes on terms used in this
        document<o:p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US">&nbsp;<o:p></o:p></span></font></strong></p>
        <p><font size="3"><span lang="EN-US">Many terms commonly used by specialists in congenital
        and genetic disorders are highly technical, <br>
        or cumbersome, or lack an internationally agreed definition, and so are unsuitable for use
        in this document, which is intended for a non-specialist, multidisciplinary audience. In
        such instances the authors have selected terms that they consider will best convey their
        meaning, though they may not exactly coincide with current expert usage. The definitions
        of these terms are as follows (62-64):</span></font></p>
        <p><span lang="EN-US"><font size="2">&nbsp;<o:p></font><font size="3">Congenital
        disorder:&nbsp; any potentially pathological condition arising before birth. This includes
        all disorders caused by environmental, genetic and unknown factors, whether they are
        evident at birth <br>
        or become manifest later in life. </font></span></span></span></span></span></span></span></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Disorder:&nbsp;
        refers to a condition potentially leading to death or disease. The term excludes minor
        congenital abnormalities.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Disability:&nbsp;
        refers to a great number of different functional limitations occurring in any
        population.&nbsp; People may be disabled by physical, intellectual or sensory impairment,
        medical conditions or <br>
        mental illness.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Prevention:
        &nbsp;reduction in the frequency and/or clinical manifestations of congenital and genetic
        disorders.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">A control programme
        for a congenital disorder:&nbsp; a comprehensive strategy combining best possible patient
        care, with prevention through community information, population screening, and genetic
        counselling (including the offer of prenatal diagnosis when appropriate).</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">A population:&nbsp;
        a defined group e.g. all those residing in a defined area, all couples planning to <br>
        marry, all pregnant women, all children with learning difficulties.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Genetic
        screening:&nbsp; a basic test that is systematically offered to a defined population, in
        order to identify a group at increased genetic risk, which may then be offered further
        tests leading to a definitive diagnosis.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Genetic
        testing:&nbsp; testing offered to people already known to be at increased genetic risk
        (e.g. the partner of a carrier of a haemoglobin disorder, an older pregnant woman, a woman
        with a fetus <br>
        with increased nuchal translucency) in order to achieve a definitive diagnosis.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Consanguinity:&nbsp;
        blood relationship, e.g. of parents to children or siblings to each other.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Consanguineous
        marriage: &nbsp;a marriage between people who are blood relatives.</span></span></span></span></span></span></span></font></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><font size="3"><span lang="EN-US">Parental
        consanguinity:&nbsp; situation when a person's parents are blood relatives.</span></font></p>
        <span lang="EN-US"><p><font size="3">Primary health care:&nbsp; first point of contact
        with the health service.&nbsp; It comprises community based health services, including
        public health components, reproductive health services, and services for front-line
        diagnosis and treatment.</font></span></p>
        <p>&nbsp;</p>
        <p><font size="3"><a name="_Toc496677286"></a><strong><a name="1. &nbsp; Introduction"><span
        lang="EN-US">1. &nbsp; Introduction</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">In December 1999 a group of WHO advisors met in Cairo
        to review the global epidemiology of congenital and genetic disorders, identify
        evidence-based interventions for their prevention and control, and recommend approaches
        for incorporating appropriate interventions into primary care services at the country
        level, making best possible use of existing infrastructures.</span></font></p>
        <p><font size="3"><span lang="EN-US">The meeting formed part of a WHO response to the
        changing pattern of health services required by populations, with a shift of focus from
        acute problems towards management of chronic disease, and from vertical programmes towards
        integrated primary health care systems. This change in emphasis that is needed is
        particularly marked in the area of child health because when infant mortality falls below
        40-50 /1000, many infants with potentially disabling conditions, who would previously have
        died undiagnosed, survive, are diagnosed, and may require life-long medical and supportive
        interventions.</span></font></span></span></span></span></span></span></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Infant mortality and
        birth rate are falling worldwide, even in the presence of serious economic problems. This
        is largely due to the implementation of simple packages of care recommended by the WHO to
        control infectious diseases and malnutrition, and improve reproductive health. Table 1
        shows that by 1996 infant mortality was less than 50/1,000 in over 65% of countries,
        including <br>
        more than 60% of the world population (1).</span></span></span></span></span></span></span></font></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><strong><span lang="EN-US"><font size="3">Table 1.&nbsp;
        Change in the past 15 years in proportion of countries, <br>
        and of the world population, in different infant mortality categories</font><font size="2">
        </font></span></strong></p>
        <table border="1" width="90%">
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">Infant mortality<a
            style="mso-footnote-id:ftn1" href="#_ftn1" name="_ftnref1" title>[1]</a><o:p></o:p></span></font></td>
            <td width="54" colspan="2" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0"
            bordercolordark="#C0C0C0" align="center"><font size="2"><span lang="EN-US">Number<br>
            &nbsp;of countries<a style="mso-footnote-id:
  ftn2" href="#_ftn2" name="_ftnref2" title>[2]</a><o:p></o:p></span></font></td>
            <td width="22" colspan="2" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0"
            bordercolordark="#C0C0C0" align="center"><font size="2"><span lang="EN-US">% of <br>
            countries<o:p></o:p></span></font></td>
            <td width="20" colspan="2" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0"
            bordercolordark="#C0C0C0" align="center"><font size="2"><span lang="EN-US">Population
            millions<o:p></o:p></span></font></td>
            <td width="20" colspan="2" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0"
            bordercolordark="#C0C0C0" align="center"><font size="2"><span lang="EN-US">% of world
            population<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center">&nbsp;</td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1981<o:p></o:p></span></font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1996<o:p></o:p></span></font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1981<o:p></o:p></span></font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1996<o:p></o:p></span></font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1981<o:p></o:p></span></font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1996<o:p></o:p></span></font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1981<o:p></o:p></span></font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">1996<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">&lt; 50<o:p></o:p></span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">98</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">151</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">52</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">68</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">2,361</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">3,469</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">47</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">61</font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">50 - 99<o:p></o:p></span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">30</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">45</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">16</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">20</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">644</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">1,870</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">13</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">33</font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">100 - 149<o:p></o:p></span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">39</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">24</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">21</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">11</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">1,367</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">358</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">27</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">6</font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">150 - 199</span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">16</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">3</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">9</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">1</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">174</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">28</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">4</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0.5</font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">200 plus<o:p></o:p></span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">5</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">3</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">19</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">0</font></td>
          </tr>
          <tr>
            <td width="58" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2"><span lang="EN-US">Total<o:p></o:p></span></font></td>
            <td width="14" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">188</font></td>
            <td width="40" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">233</font></td>
            <td width="12" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">100</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">100</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">4,971</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">5,725</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">100</font></td>
            <td width="10" bordercolor="#C0C0C0" bordercolorlight="#C0C0C0" bordercolordark="#C0C0C0"
            align="center"><font size="2">100</font></td>
          </tr>
        </table>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt"><font size="2"><span lang="EN-US">&nbsp;<o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">Available evidence indicates that the birth
        prevalence and potential burden of congenital disorders <br>
        in developing countries is at least as great, and in many instances is greater than in
        more developed countries. There is therefore growing recognition of the need for an
        integrated global attack on congenital disorders, including services for diagnosis, best
        possible patient care and prevention. <br>
        The initiative should be developed as soon as possible to maximize its long-term
        cost-effectiveness.</span></font></span></span></span></span></span></span></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">The causes of
        congenital disorders are numerous and varied, and multiple approaches are required. The
        initiative should therefore start by focusing on selected interventions that are effective
        in reducing health burden, are as simple as possible, can be implemented in primary health
        care, and provide a basis for further service development. Mechanisms for assessing
        implementation of the interventions, and the effect on health burden are integral to the
        programme.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Country differences
        in epidemiology, demographic factors, organization of health systems, priorities, and
        available resources mean that no standard set of interventions can be recommended for
        worldwide application. Some interventions can be confidently recommended in any
        circumstances, but for others the epidemiology of the target conditions is undefined,
        and/or it is uncertain that <br>
        results will resemble those documented elsewhere.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">The chosen approach
        is therefore to design a programme of work that will support an organized approach to the
        control of congenital disorders in any country. This falls into three distinct phases. The
        first, development of a country plan, requires assessment of the local epidemiology and
        health burden of congenital disorders, definition of priorities, selection&nbsp; of
        feasible interventions, and assessment of resources required. The second phase is a
        demonstration project implementing the chosen interventions in a defined setting,
        including audit of process and impact on the health burden of the selected disorders. The
        final phase is countrywide implementation of the chosen interventions. The programme of
        work will be conducted as a collaborative international study, supported by the latest
        evidence, and with access to guidelines and tools available through the WHO. The project
        is seen as initiating a major health care initiative, which will be built on progressively
        over the years.</span></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">The following steps
        are proposed for participating countries. </span></span></span></span></span></span></span></font></p>
        <p align="left" style="text-align:left;mso-list:l6 level1 lfo41"><font size="3"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phase - development of
        the country plan:<o:p></o:p></span></span></span></span></span></span></span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convene a
        national multidisciplinary task force, to design and supervise the programme of work.
        Their first task is to produce a structured country report on present knowledge <br>
        of congenital and genetic disorders. This will include assessment of the current
        situation, <br>
        local priorities and available resources; choice of appropriate interventions; outline of
        a country plan. The task force will liaise closely with the WHO.</span></span></span></span></span></span></span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Design and
        conduct a pilot for the proposed WHO epidemiological study of the birth prevalence of
        congenital disorders.</span></span></span></span></span></span></span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><font
        size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conduct an
        epidemiological study. This will provide baseline data on the local epidemiology and
        health burden of selected congenital disorders, support selection of appropriate
        interventions, establish mechanisms for surveillance, and allow assessment of <br>
        the feasibility of the interventions on a national scale, and manpower and training
        requirements.</span></font></p>
        <p align="left"
        style="margin-left:18.0pt;text-align:left;
text-indent:-18.0pt;mso-list:l6 level1 lfo41;tab-stops:-72.0pt -36.0pt list 18.0pt"><span
        lang="EN-US"><font size="2">2. &nbsp;&nbsp;&nbsp;</font><font size="3">&nbsp;&nbsp; Phase
        2 - the intervention study</font></span></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Develop staff training packages,
        and establish systems for staff training.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initiate the selected
        interventions in a large-scale demonstration project, in a defined setting.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluate process and outcomes,
        including estimated impact on the health burden of the selected disorders.</span></font></p>
        <p align="left"
        style="margin-left:18.0pt;text-align:left;
text-indent:-18.0pt;mso-list:l12 level1 lfo32;tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phase 3 - national
        implementation:&nbsp; will be developed according to the experience gained in
        &nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;&nbsp; the first two phases. </font></p>
        <p><font size="3">This report briefly reviews existing information on the scope of the
        problem and the range of appropriate interventions, outlines priorities identified at the
        meeting, identifies areas where further information is needed, and suggests how approaches
        deployed in more developed countries may <br>
        be adjusted to meet the stringent cost-effectiveness requirements of less developed
        countries.</font></p>
        <p><strong><font size="3"><a
        name="2.&nbsp;&nbsp; Global epidemiology and health burden of congenital disorders">2.&nbsp;&nbsp;
        Global epidemiology and health burden of congenital disorders</a></font></strong></span></p>
        <p><font size="3"><span lang="EN-US">The frequency of congenital disorders is best
        described in terms of potential birth prevalence, i.e. <br>
        as affected births/1,000 in the absence of a prevention programme. Prevalence varies
        considerably between populations due to differences in genetic make-up and demographic and
        environmental factors. Annex 1 summarizes data on the baseline birth prevalence of
        congenital disorders with a genetic component for populations of Northern European origin
        (2). Experience in many parts of <br>
        the world shows that lower figures are usually due to under-diagnosis and under-reporting
        (3, 4): <br>
        for example recent studies have overturned previous reports of a low birth prevalence of
        neural <br>
        tube defects and Down syndrome in black South Africans (5). These figures exclude
        disability exclusively due to environmental causes or of undifferentiated or undetermined
        aetiology, and so <br>
        tend to under-estimate the totality of physical and mental disability arising before
        birth. For <br>
        example cerebral palsy, epilepsy, and conditions such as mental retardation due to
        maternal iodine <br>
        deficiency, fetal alcohol syndrome, and deafness caused by maternal rubella infection,
        which are commonest in less developed countries, are not included. Nevertheless, in the
        absence of reliable data from these countries, the figures offer a provisional starting
        point for a minimum estimate of the global birth prevalence of serious congenital
        disorders.</span></font></p>
        <p><font size="3"><span lang="EN-US">Table 2 gives minimum estimates of the birth
        prevalence of congenital disorders by WHO region, based on the data for Northern European
        populations, with the addition of data for haemoglobin disorders (6) and
        glucose-6-phosphate dehydrogenase deficiency (7), and adjustment for the effect of
        customary consanguineous marriage (8). They clearly show the greater potential health
        burden of congenital disorders in most developing countries.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">Table 2.&nbsp; Minimum estimates for the
        birth prevalence of infants with serious congenital disorders, by WHO region (calculations
        using data in refs 1,2, 6, 7, 8)</span></font></strong></p>
        <table border="1" width="537" height="297">
          <tr>
            </span></span></span></span></span><td width="90" align="center" height="84"><font
            size="2"><span lang="EN-US">WHO Region<o:p></o:p></span></font></td>
            <td width="68" align="center" height="84"><font size="2"><span lang="EN-US">Population,
            millions, 1996<o:p></o:p></span></font></td>
            <td width="55" align="center" height="84"><font size="2"><span lang="EN-US">Births/yr
            millions, 1996<o:p></o:p></span></font></td>
            <td width="66" align="center" height="84"><font size="2"><span lang="EN-US">Congenital
            malform -ations /1000<o:p></o:p></span></font></td>
            <td width="60" align="center" height="84"><font size="2"><span lang="EN-US">Chromo- somal
            disorders /1000<o:p></o:p></span></font></td>
            <td width="57" align="center" height="84"><font size="2"><span lang="EN-US">Single gene
            disorders /1000<o:p></o:p></span></font></td>
            <td width="63" align="center" height="84"><font size="2"><span lang="EN-US">Total
            congenital disorders /1000<o:p></o:p></span></font></td>
            <td width="61" align="center" height="84"><font size="2"><span lang="EN-US">Annual
            affected live-births</span></font></td>
            <span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
            lang="EN-US">
          </tr>
          <tr>
            <td width="90" align="center" height="38"><font size="2"><span lang="EN-US">Eastern
            Mediterranean <o:p></o:p></span></font></td>
            <td width="68" align="center" height="38"><font size="2">506</font></td>
            <td width="55" align="center" height="38"><font size="2">18.1</font></td>
            <td width="66" align="center" height="38"><font size="2">35.7</font></td>
            <td width="60" align="center" height="38"><font size="2">4.3</font></td>
            <td width="57" align="center" height="38"><font size="2">27.3</font></td>
            <td width="63" align="center" height="38"><font size="2">69</font></td>
            <td width="61" align="center" height="38"><font size="2">1,237,225</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="21"><font size="2"><span lang="EN-US">African<o:p></o:p></span></font></td>
            <td width="68" align="center" height="21"><font size="2">540</font></td>
            <td width="55" align="center" height="21"><font size="2">23.0</font></td>
            <td width="66" align="center" height="21"><font size="2">30.8</font></td>
            <td width="60" align="center" height="21"><font size="2">4.4</font></td>
            <td width="57" align="center" height="21"><font size="2">25.0</font></td>
            <td width="63" align="center" height="21"><font size="2">61</font></td>
            <td width="61" align="center" height="21"><font size="2">1,412,427</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="21"><font size="2"><span lang="EN-US">S.E. Asian<o:p></o:p></span></font></td>
            <td width="68" align="center" height="21"><font size="2">1,401</font></td>
            <td width="55" align="center" height="21"><font size="2">38.2</font></td>
            <td width="66" align="center" height="21"><font size="2">31.0</font></td>
            <td width="60" align="center" height="21"><font size="2">3.9</font></td>
            <td width="57" align="center" height="21"><font size="2">14.7</font></td>
            <td width="63" align="center" height="21"><font size="2">51</font></td>
            <td width="61" align="center" height="21"><font size="2">1,946,606</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="21"><font size="2"><span lang="EN-US">European <o:p></o:p></span></font></td>
            <td width="68" align="center" height="21"><font size="2">867</font></td>
            <td width="55" align="center" height="21"><font size="2">10.8</font></td>
            <td width="66" align="center" height="21"><font size="2">31.3</font></td>
            <td width="60" align="center" height="21"><font size="2">3.7</font></td>
            <td width="57" align="center" height="21"><font size="2">12.4</font></td>
            <td width="63" align="center" height="21"><font size="2">49</font></td>
            <td width="61" align="center" height="21"><font size="2">522,832</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="21"><font size="2"><span lang="EN-US">American<o:p></o:p></span></font></td>
            <td width="68" align="center" height="21"><font size="2">782</font></td>
            <td width="55" align="center" height="21"><font size="2">16.2</font></td>
            <td width="66" align="center" height="21"><font size="2">30.9</font></td>
            <td width="60" align="center" height="21"><font size="2">3.8</font></td>
            <td width="57" align="center" height="21"><font size="2">11.9</font></td>
            <td width="63" align="center" height="21"><font size="2">48</font></td>
            <td width="61" align="center" height="21"><font size="2">774,235</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="38"><font size="2"><span lang="EN-US">Western
            Pacific<o:p></o:p></span></font></td>
            <td width="68" align="center" height="38"><font size="2">1,650</font></td>
            <td width="55" align="center" height="38"><font size="2">31.3</font></td>
            <td width="66" align="center" height="38"><font size="2">30.6</font></td>
            <td width="60" align="center" height="38"><font size="2">3.5</font></td>
            <td width="57" align="center" height="38"><font size="2">11.4</font></td>
            <td width="63" align="center" height="38"><font size="2">47</font></td>
            <td width="61" align="center" height="38"><font size="2">1,464,067</font></td>
          </tr>
          <tr>
            <td width="90" align="center" height="21"><font size="2"><span lang="EN-US">Total<o:p></o:p></span></font></td>
            <td width="68" align="center" height="21"><font size="2">5,746</font></td>
            <td width="55" align="center" height="21"><font size="2">137.6</font></td>
            <td width="66" align="center" height="21"><font size="2">31.5</font></td>
            <td width="60" align="center" height="21"><font size="2">3.9</font></td>
            <td width="57" align="center" height="21"><font size="2">16.8</font></td>
            <td width="63" align="center" height="21"><font size="2">53</font></td>
            <td width="61" align="center" height="21"><font size="2">7,357,392</font></td>
          </tr>
        </table>
        <p><font size="2"><span lang="EN-US">&nbsp;<o:p></o:p></span></font><font size="3">Table 3 gives
        estimates for the morbidity and mortality associated with the main groups of disorder <br>
        in developed countries, even with best possible management, and the types of service
        required (9-11). In less developed countries mortality is far higher.</font></p>
        </span></span></span></span></span><p><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><strong><font size="3"><span
        lang="EN-US">Table 3.&nbsp; Estimated outcome for different types of congenital disorders
        in developed countries (Refs. 9-11)</span></font></strong></p>
        <table border="1" width="85%">
          <tr>
            <td width="16%" rowspan="2"><p align="center"><font size="2"><span lang="EN-US">Category
            of disorder<o:p></o:p></span></font></td>
            <td width="16%" rowspan="2"><p align="center"><font size="2"><span lang="EN-US">Births/1000
            (est)<o:p></o:p></span></font></td>
            <td width="15%" rowspan="2"><font size="2"><span lang="EN-US">Main therapeutic needs<o:p></o:p></span></font></td>
            <td width="53%" colspan="3"><p align="center"><font size="2"><span lang="EN-US">Outcome, %
            of cases<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="14%"><font size="2"><span lang="EN-US">Early mortality<o:p></o:p></span></font></td>
            <td width="15%"><font size="2"><span lang="EN-US">Chronic problems</span></font></td>
            <td width="24%"><font size="2"><span lang="EN-US">Treat-ment successful<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="16%"><font size="2"><span lang="EN-US">Major congenital malformations<o:p></o:p></span></font></td>
            <td width="16%"><p align="center"><font size="2"><span lang="EN-US">31.3<o:p></o:p></span></font></td>
            <td width="15%"><font size="2"><span lang="EN-US">Paediatric surgery, social support<o:p></o:p></span></font></td>
            <td width="14%"><p align="center"><font size="2"><span lang="EN-US">22<o:p></o:p></span></font></td>
            <td width="15%"><p align="center"><font size="2"><span lang="EN-US">24<o:p></o:p></span></font></td>
            <td width="24%"><p align="center"><font size="2"><span lang="EN-US">54<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="16%"><font size="2"><span lang="EN-US">Chromosomal disorders<o:p></o:p></span></font></td>
            <td width="16%"><p align="center"><font size="2"><span lang="EN-US">3.7<o:p></o:p></span></font></td>
            <td width="15%"><font size="2"><span lang="EN-US">Social support<o:p></o:p></span></font></td>
            <td width="14%"><p align="center"><font size="2"><span lang="EN-US">34<o:p></o:p></span></font></td>
            <td width="15%"><p align="center"><font size="2"><span lang="EN-US">64<o:p></o:p></span></font></td>
            <td width="24%"><p align="center"><font size="2"><span lang="EN-US">2<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="16%"><font size="2"><span lang="EN-US">Single gene disorders<a
            style="mso-footnote-id:ftn3" href="#_ftn3" name="_ftnref3" title>[3]</a><o:p></o:p></span></font></td>
            <td width="16%"><p align="center"><font size="2"><span lang="EN-US">7.0<o:p></o:p></span></font></td>
            <td width="15%"><font size="2"><span lang="EN-US">Medical management, social support<o:p></o:p></span></font></td>
            <td width="14%"><p align="center"><font size="2"><span lang="EN-US">58<o:p></o:p></span></font></td>
            <td width="15%"><p align="center"><font size="2"><span lang="EN-US">31<o:p></o:p></span></font></td>
            <td width="24%"><p align="center"><font size="2"><span lang="EN-US">11<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="16%"><font size="2"><span lang="EN-US">TOTAL<o:p></o:p></span></font></td>
            <td width="16%"><p align="center"><font size="2"><span lang="EN-US">42.0<o:p></o:p></span></font></td>
            <td width="15%">&nbsp;</td>
            <td width="14%"><p align="center"><font size="2"><span lang="EN-US">29<o:p></o:p></span></font></td>
            <td width="15%"><p align="center"><font size="2"><span lang="EN-US">28<o:p></o:p></span></font></td>
            <td width="24%"><p align="center"><font size="2"><span lang="EN-US">43<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p><font size="3"><span lang="EN-US">Table 4 shows the major contribution of lethal
        congenital disorders to global infant mortality. In <br>
        many developed countries infant mortality is now lower than the birth prevalence of
        potentially <br>
        lethal congenital disorders. This reflects the combined effects of widespread
        implementation of <br>
        public health measures for primary prevention, cure when feasible (e.g. paediatric
        surgery), <br>
        long-term management that prolongs life when cure is not feasible, and prevention through <br>
        prenatal diagnosis and selective abortion.</span></font></span></span></span></span></span></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><strong><font size="3"><span lang="EN-US">Table 4.&nbsp; Comparison of infant
        mortality and birth prevalence of potentially lethal congenital disorders,&nbsp; by WHO
        Region &nbsp; (Data from 1996 UN demographic<br>
        yearbook and refs 6-8 and 9-11.)</span></font></strong></p>
        <table border="1" width="89%">
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">WHO Region<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Infant mortality<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Congenital disorders /1000<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Potentially lethal congenital
            disorders/1000<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Potentially lethal,<br>
            &nbsp;% of infant mortality</span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Eastern Mediterranean</span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">85.1<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">69<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">32<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">38<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">African </span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">91.6<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">61<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">23<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">25<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">South East Asian</span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">72.8<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">51<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">15<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">21<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">European</span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">17.0<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">49<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">15<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">87<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">American<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">31.7<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">48<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">13<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">42<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Western Pacific<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">41.5<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">47<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">12<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">30<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Total<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">61.2<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">53<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">18<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">29<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p><font size="2"><br>
        <a name="_Toc496677288"></a></font><font size="3"><a
        name="2.1&nbsp; Dilemmas for health services"><strong>2.1&nbsp; Dilemmas for health
        service</strong>s</a></font></p>
        <p><font size="3"><span lang="EN-US">Some congenital disorders can be partially prevented
        by public education (e.g. Down syndrome, neural tube defects, or complications of G6PD
        deficiency), and some can be relatively simply corrected (e.g. club foot, cryptorchidism,
        cleft lip and palate, patent ductus arteriosus, ventricular septal defect). However, many
        cause early death or require life-long, expensive and labour-intensive management.</span></font></p>
        <p><font size="3"><span lang="EN-US">The burden for individuals, families and society is
        determined by the birth prevalence of affected infants; their survival; availability,
        costs and effectiveness of treatment; availability of social support; and the extent to
        which affected individuals are accepted and integrated into society. Service requirements
        at any given point in time depend on the number of living patients in the population.</span></font></span></span></span></span></span></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US">When affected infants do not survive,
        population prevalence (affected individuals /1,000) is a <br>
        fraction of birth prevalence. However, once diagnosis and treatment become available
        population prevalence rises towards birth prevalence, and the rate of rise is a measure of
        the availability and effectiveness of treatment. That is:</span></span></span></span></span></span></font></p>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt"><font size="3"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">Population
        prevalence = birth prevalence x&nbsp; average survival of affected individuals (yr)<o:p></o:p></span></span></span></span></span></span></font></p>
        <p style="margin-left:219.75pt;text-indent:-14.2pt"><font size="3"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US">&nbsp;average
        survival of the general population (yr)</span></span></span></span></span></span></font></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><font size="3"><span lang="EN-US">The evolution of health services therefore
        inevitably leads to a cumulative increase in numbers needing care, because patients live
        longer. It also usually leads to an increase in annual cost per patient because cost of
        care usually rises as treatment possibilities improve. These combined <br>
        effects can have very serious implications.</span></font></p>
        <p><font size="3"><span lang="EN-US">This process is just beginning in countries where
        infant mortality has recently fallen below 50/1,000. The resultant dilemmas can be
        illustrated using the example of thalassaemia, the presenting genetic problem in many
        countries. Children with thalassaemia major are easy to diagnose, and regular <br>
        blood transfusion is available in most countries, is life saving and gives excellent
        short-term quality <br>
        of life. However, in the absence of iron chelation therapy it leads to death from iron
        overload at 12 <br>
        to 24 years of age, so once transfusion treatment has been started patients, parents and
        health workers make great efforts to obtain iron chelation therapy to ensure long-term
        survival. Conventional treatment by subcutaneous infusion of desferrioxamine is so
        burdensome and <br>
        expensive that bone marrow transplantation (when practicable) is a cost-effective
        alternative (6, 12). Thus major costs are bound to fall on the health service, the family,
        or both, and the majority of patients worldwide cannot obtain adequate long-term
        treatment. Figure 1 presents the cost implications in a format that can be applied for any
        country, when the expected annual number of affected births is known (calculations of Dr B
        Modell).</span></font></span></span></span></span></span></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><strong><font size="3"><span lang="EN-US">Figure 1.&nbsp; Cumulative annual
        treatment costs when one patient<br>
        &nbsp;with thalassaemia is born per year</span></font></strong><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><img
        src="clip_image003.gif" v:shapes="_x0000_i1025" width="532" height="297"></span></p>
        <p style="margin-top:0cm;margin-right:21.15pt;margin-bottom:
6.0pt;margin-left:36.0pt"></span></span></span></span></span>&nbsp;</p>
        <span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><p><font size="2"><span lang="EN-US"><a style="mso-footnote-id:ftn1"
        href="#_ftnref1" name="_ftn1" title>[1]</a> Infant mortality rate (IMR) = deaths under 1
        year of age per 1000 live births.</span></font></p>
        <p><font size="2"><span lang="EN-US"><a style="mso-footnote-id:ftn2" href="#_ftnref2"
        name="_ftn2" title>[2]</a> The number of countries with data in the UN Demographic
        Yearbook series increased from <br>
        188 in 1981 to 223 in 1996.</span></font></p>
        <p><font size="2"><span lang="EN-US"><a style="mso-footnote-id:ftn3" href="#_ftnref3"
        name="_ftn3" title>[3]</a> The figure for single gene disorders includes only those with
        onset in infancy or early childhood.&nbsp; It excludes dominantly inherited late-onset
        disorders such as familial hypercholesterolaemia.</span></font></p>
        </span></span></span></span></span><p><font size="3"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US">Figures can be adapted for any country
        by multiplying by annual affected births. Costs with three different treatment
        &#147;policies&#148; are projected from a notional date when the policy is initiated. The
        lowest curve shows the cost of adequate regular blood transfusion without iron chelation
        therapy: cost escalation is limited because patients live less than 20 years. The middle
        curve shows costs rise with adequate transfusion but half the recommended level of iron
        chelation therapy, giving patient survival of up to 30 years. The upper curve shows costs
        with optimal treatment including iron chelation therapy as recommended, giving long-term
        patient survival.</span></span></span></span></span></font></p>
        <p style="margin-top:0cm;margin-right:21.15pt;margin-bottom:
6.0pt;margin-left:36.0pt"><font
        size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US">&nbsp;<o:p></o:p></span></span></span></span></span></span></font></p>
        <p><font size="3"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US">For example, in Iran the average birth
        prevalence of thalassaemia major is 0.74/1000, and the proportion of patients expected to
        survive at least into their late teens has risen from practically <br>
        none thirty years ago to over 90% today. Over 15,000 patients are currently under care,
        representing a forward commitment of around $200 million per year for at least the next
        thirty <br>
        years (Dr A. Samavat, personal communication). In the absence of prevention, annual
        treatment costs could rise to over $700 million per year. </span></span></span></span></span></span></font></p>
        <p><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><font size="3"><span lang="EN-US">Countries with limited resources are
        necessarily interested in more cost-efficient treatment. For example a new oral iron
        chelating agent (deferiprone) that is more acceptable to patients and potentially cheaper
        than desferrioxamine has long been used in India, and is gaining wider <br>
        acceptance in industrialized countries (13). Though cheaper treatment can reduce the rate
        of cost escalation, it does not reduce the need for prevention.</span></font></p>
        </span></span></span></span></span><p><span lang="EN-US"><span lang="EN-US"><span
        lang="EN-US"><span lang="EN-US"><span lang="EN-US"><strong><font size="3"><span
        lang="EN-US">Table 5.&nbsp; Estimated costs of treatment and prevention for thalassaemia,<br>
        in countries of the WHO Eastern Mediterranean Region. &nbsp; (Refs. 1,6,12)</span></font></strong></p>
        <table border="1" width="100%">
          <tr>
            <td width="12%">&nbsp;</td>
            <td width="12%"><font size="2"><span lang="EN-US">Annual births beta<o:p></o:p></span></font></td>
            <td width="24%" colspan="2"><font size="2"><span lang="EN-US">Annual cost of optimal
            treatment (no prevention) ($1000s)<o:p></o:p></span></font></td>
            <td width="26%" colspan="2"><font size="2"><span lang="EN-US">Annual cost of prevention
            ($1000s)<o:p></o:p></span></font></td>
            <td width="26%" colspan="2"><font size="2"><span lang="EN-US">Annual cost, <br>
            treatment/prevention<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="12%">&nbsp;</td>
            <td width="12%"><font size="2"><span lang="EN-US">Thalassaemia major<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">Yr 1 = <br>
            1 birth cohort<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">Yr 10 = <br>
            10 birth cohorts<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">Year 1<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">Year 10<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">Year 1<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">Year 10</span></font></td>
          </tr>
          <tr>
            <td width="12%"><font size="2"><span lang="EN-US">Pakistan<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">3,087<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">30,564<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">305,635<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">16,549<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">16,549<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.8<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">18.5<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Iran<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">1,251<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">12,387<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">123,874<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">7,730<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">7,730<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.6<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">16.0<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Egypt<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">654<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">6,479<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">64,794</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">4,753</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">4,753<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.4<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">13.6<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Iraq<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">571</font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">5,648<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">56,482<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">3,408</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">3,408<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.7<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">16.6<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Syria<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">521<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">5,162<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">51,620<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">2,868</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">2,868<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.8<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">18.0<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Saudi Arabia<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">341<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">3,380<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">33,797<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">2,423<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">2,423<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.4<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">13.9</font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Jordan<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">90<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">671<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">6,712<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">449<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">449<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.5<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">15.0</font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Cyprus<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">68<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">894<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">8,943<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">394<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">394<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">2.3<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">22.7<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Palestine<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">48<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">476</font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">4,758</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">291</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">291<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.6<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">16.3<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Lebanon</font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">46<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">456<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">4,557<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">284<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">284</font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.6<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">16.0<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Oman<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">26<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">139<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">1,394<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">152<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">152<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">0.9<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">9.2<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">UAE<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">19<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">258<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">2,575<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">151<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">151<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.7<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">17.1<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Bahrain</font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">14<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">186<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">1,864<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">106<o:p></o:p></font></span></td>
            <td width="13%">&nbsp;</td>
            <td width="13%"><span lang="EN-US"><font size="2">1.8<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">17.7<o:p></o:p></font></span></td>
          </tr>
          <tr>
            <td width="12%"><span lang="EN-US"><font size="2">Qatar<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">6<o:p></o:p></font></span></td>
            <td width="12%"><span lang="EN-US"><font size="2">55<o:p></o:p></font></span></td>
            <td width="12%">&nbsp;</td>
            <td width="13%"><span lang="EN-US"><font size="2">34<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">553<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">1.6<o:p></o:p></font></span></td>
            <td width="13%"><span lang="EN-US"><font size="2">16.3<o:p></o:p></font></span></td>
          </tr>
        </table>
        <p></span></span></span></span><font size="3">National programmes of community
        information, carrier screening and counselling, and availability of prenatal diagnosis
        have greatly reduced the birth prevalence of thalassaemia major in all countries where
        they have been established (10, 14-17). In Iran a national prevention programme is now
        under development, and a national patient register already shows evidence of a reduction
        in affected births.</font></span></p>
        <p><font size="3"><span lang="EN-US">Table 5 compares estimated annual and 10 year
        projected costs for treating thalassaemia, with the estimated annual cost of prevention,
        for countries of the WHO Eastern Mediterranean Region. In most countries the estimated
        annual cost of prevention approximately equals the cost of treating one annual birth
        cohort of patients for one year. Annual prevention costs are effectively constant but
        annual treatment costs rise year-on-year, so the cost-effectiveness of prevention
        increases with every year that it is in place. The 10-year projection shows that it is
        impossible for most countries to provide optimal treatment for all patients who may be
        born, and that effective prevention is a necessary condition for those already living to
        be treated adequately.</span></font></p>
        <p><font size="3"><span lang="EN-US">The same general principle applies for many other
        congenital disorders including sickle cell disorders, haemophilia, cystic fibrosis,
        phenylketonuria, Down syndrome and neural tube defects.</span></font></p>
        <p><font size="3"><span lang="EN-US">The earlier effective interventions are implemented,
        the greater their value to families and society, while every year that passes without a
        national strategy contributes to long-term problems. For example in Cyprus a policy of
        community education and premarital screening has reduced affected births to less than 5%
        of expectation, and stabilized the annual cost of patient care at a small fraction of the
        projected cost (16). By contrast in the UK where there is no national policy, screening is
        part of pregnancy care, and only 50% of at risk couples are detected in time for the offer
        of prenatal diagnosis (17), the annual cost of treatment is 50% of the projected cost.</span></font></p>
        <p><font size="3"><a name="_Toc496677289"></a><strong><span lang="EN-US"><a
        name="2.2&nbsp; The burden for families">2.2&nbsp; The burden for families</a> </span></strong></font></p>
        <p><font size="3"><span lang="EN-US">The main emphasis so far in discussing the service
        dilemmas associated with reduced infant mortality has been on financial costs, because of
        the obvious importance of this dimension to policymakers. High treatment costs make
        conditions such as thalassaemia and haemophilia highly &#147;visible&#148; to health
        services, but many equally serious disorders have smaller cost implications for medical
        services and so are less visible, though the burden for the family (and such social
        services as are available) is as heavy or even heavier. This group includes conditions
        like Down syndrome or sickle cell disorders, that are increasing in prevalence because
        they are particularly responsive to basic primary health care interventions. Thus the need
        for early planning for best possible care and effective prevention applies for the full
        spectrum of congenital disorders. </span></font></p>
        <p><font size="3"><span lang="EN-US">For policy purposes, the more visible disorders may
        be seen as indicator conditions, capable of reflecting both improvements in basic medical
        services, and the likely total burden of congenital disorders in the community.</span></font></p>
        <p><font size="3"><span lang="EN-US">Table 6 gives some examples showing that even in the
        absence of specialist services, appropriately trained primary health care workers can do a
        great deal to improve survival and quality of life for people with congenital disorders.
        More detailed possibilities for diagnosis, management counselling and support at the
        primary health care level are given in Annex 2.</span></font></p>
        <p><font size="3"><span lang="EN-US">Further work is needed on developing scientific
        principles and methods for describing the epidemiology of congenital disorders, measuring
        the financial and non-financial burden they impose on patients, families and communities,
        and planning appropriate approaches at the primary health care level. </span></font></p>
        <p><strong><font size="3"><span lang="EN-US">Table 6.&nbsp; Some suggested&nbsp;
        interventions for improving prognosis and quality of life of people with common inherited
        disorders, and their families (Refs. 7, 10, 18, 63)</span></font></strong></p>
        <table border="1" width="100%">
          <tr>
            <td width="25%"><font size="2"><span lang="EN-US">Condition<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Detection<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Intervention<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Benefit<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="25%"><font size="2"><span lang="EN-US">Sickle cell disorders<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Neonatal screening </span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Advice for parents on protection &amp;
            avoidance of sickle cell crises: prophylactic penicillin and anti-malarials:&nbsp; genetic
            counselling<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Increased survival and acceptance in the
            family, decreased hospitalization and over-protection, integration into society<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="25%"><font size="2"><span lang="EN-US">G6PD deficiency<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Neonatal screening</span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Avoiding precipitating factors such as
            moth-balls in baby clothes, and some traditional remedies<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Reduced neonatal jaundice, heightened
            awareness and early diagnosis<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="25%"><font size="2"><span lang="EN-US">G6PD deficiency<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Public information<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Educating parents not to give broad
            beans to children<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Decreased paediatric admissions for
            favism<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="25%"><font size="2"><span lang="EN-US">Oculo-cutaneous albinism</span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Clinical neonatal diagnosis<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Protection from sun with clothing, sun
            block cream. Visual assessment &amp; glasses.<o:p></o:p></span></font></td>
            <td width="25%"><font size="2"><span lang="EN-US">Reduced incidence of skin disorders and
            skin cancer: improved survival<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p align="left" style="text-align:left"><font size="3"><a name="_Toc496677290"></a><strong><a
        name="2.3&nbsp; Identifying priorities and key conditions for intervention"><span
        lang="EN-US">2.3&nbsp; Identifying priorities and key conditions for intervention</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Despite their variety and diverse causes, it is
        possible to identify priorities, and select appropriate target conditions, for a
        demonstration project on prevention and management of congenital disorders:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Congenital malformations: &nbsp;neural tube defects provide an excellent &#147;point of
        entry&#148; for an initiative aiming to reduce the burden of congenital malformations
        because (a) they are so obvious that they are rarely missed in newborns, and reliable
        audit data can be collected - providing they are registered; (b) many may be prevented by
        periconceptional dietary folate supplementation for women; (c) the majority can be
        detected antenatally by ultrasound scanning, permitting the option of termination of
        pregnancy; (d) generic approaches developed for these disorders can be extended across the
        full spectrum of congenital malformations, with time.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Chromosomal disorders: &nbsp;Down syndrome provides the appropriate point of entry for
        chromosomal disorders because (a) its birth prevalence can be greatly reduced by family
        planning; (b) survival and quality of life can be improved by information and relatively
        simple management strategies, and community support associations can be very helpful for
        families; (c) when karyotyping is available women at increased risk (e.g. on grounds of
        maternal age) can be offered prenatal diagnosis; (d) primary health care workers can be
        taught to make and report the clinical diagnosis, so birth prevalence can be monitored,
        and (e) laboratory-based registers can be used to audit prenatal diagnosis.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Inherited disorders:&nbsp; haemoglobin disorders are a common point of entry for
        strategies aiming to reduce the burden of inherited disorders because (a) they are highly
        prevalent in many populations; (b) survival and quality of life can be greatly improved by
        simple protective measures for sickle cell disorders and transfusion programmes for
        thalassaemia; (c) carriers can be detected by cheap and simple haematological tests, and
        carrier couples can be advised prospectively of their risk; (d) prenatal diagnosis is
        highly acceptable to couples at risk; (e) diagnosis registers can be used for service
        audit; (f) screening strategies and DNA-based laboratory methods introduced for
        haemoglobin disorders can be extended for other inherited disorders, with time.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Customary consanguineous marriage: a culturally appropriate approach for genetic
        counselling in relation to consanguineous marriage is required. A significant proportion
        of the estimated regional differences in birth prevalence of congenital disorders, shown
        in Table 2, is related to the genetic effect of customary consanguineous marriage. </span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HIV/AIDS
        is an increasingly important cause of congenital disability and childhood death in most
        countries, and is the dominant cause in Africa. Approaches for reducing its birth
        prevalence must be integrated with any other programme for prevention of congenital
        disorders and disability. Liaison at WHO level on this topic between the human genetics,
        reproductive health and AIDS programmes is essential.</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 36.0pt 62.4pt 127.6pt"><font size="3"><span
        lang="EN-US">The planned initiative will help to fill important gaps in our knowledge of
        the public health importance of several common congenital disorders. For example,
        glucose-6-phospate dehydrogenase (G6PD) deficiency is an important cause of neonatal
        jaundice and life-threatening favism in South East Asia, the Mediterranean area and parts
        of the Middle East, but there is inadequate quantitative information on the actual burden
        in these areas, and the clinical effect of the milder mutations that are highly prevalent
        in Africa is almost completely undocumented (18). There is little information from
        developing countries on the potential burden of Rhesus incompatibility, and more is needed
        from Africa and other regions on the prevalence and burden of oculo-cutaneous albinism
        (19). <o:p></o:p></span></font></p>
        <p><font size="3"><a name="_Toc496677291"></a><strong><a
        name="3.&nbsp; Basic reproductive health approaches"><span lang="EN-US">3.&nbsp; Basic
        reproductive health approaches</span></a></strong></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 36.0pt 62.4pt 127.6pt"><span lang="EN-US"><font
        size="3">When the following relatively simple and effective measures are incorporated into
        primary health care and reproductive health services, many serious disorders will be
        prevented from arising in the first instance. <o:p></font></span></p>
        <p><font size="3"><a name="_Toc496677292"></a><strong><a name="3.1&nbsp; Family planning"><span
        lang="EN-US">3.1&nbsp; Family planning</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Availability of family planning has an important
        effect on the burden of congenital disorders. Once couples have a high expectation of
        their children's survival, and family planning is available, most stop reproducing
        when they have the desired number of children. Figure 2 shows the evolution of the
        relationship between infant mortality and birth rate. For example in Iran infant mortality
        has fallen by 75% (from 108 to 26/1,000) in the past 15 years. Family planning is provided
        through the primary health care system, and the crude birth rate has now fallen by 58%,
        from 43 to 18/1000 (1). Thus though the population has increased by 50% the annual number
        of children born with congenital disorders has fallen by 38%. For example (potential)
        births of children with thalassaemia major have fallen from over 1,200 to about 860 per
        year.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">Figure 2.&nbsp; Relationship between infant
        mortality and crude birth rate,<br>
        1981 compared with 1996</span></font></strong></p>
        <p>&nbsp;<span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:429.75pt;
 height:546.75pt' fillcolor="window">
 <v:imagedata src="/ncd/asthma/whologo.jpg" o:title=""/>
</v:shape><![endif]--><img
        width="573" height="729" src="clip_image002.gif" v:shapes="_x0000_i1025"></p>
        </span><p>&nbsp;</p>
        <p style="margin-left:36.0pt;page-break-after:avoid"><span lang="EN-US"><font size="3">The
        graphs contain a point for every country with data in the relevant UN Demographic Yearbook
        series (1). They show the general tendency for birth rate to fall when infant mortality
        falls below about 75/ 1000. The wide range of birth rate associated with a given infant
        mortality reflects availability of family planning, the extent to which it is promoted,
        and cultural conventions. (Four 1996 outliers with infant mortality 50/1000 or less but
        birth rate over 40/1000 are: Solomon Islands, Wallis and Futuna island (both WPR), Sao
        Tome and Principe (AFR), and Oman (EMR). American Samoa has an infant mortality of 11/1000
        and a crude birth rate of 38/1000.)<o:p></font></span></p>
        <p style="page-break-after:avoid"><font size="3"><span lang="EN-US">Family planning
        usually leads to a particularly marked reduction in births to women over 35 years of age,
        and so to an even greater reduction in the number of children born with Down syndrome,
        because birth prevalence is strongly related to maternal age. In Europe the average
        calculated birth prevalence of Down syndrome fell by around 60% (from 2.5 to 1.0/1000)
        between 1950 and 1975, as use of family planning increased (9, 20). A similar effect can
        be safely predicted in any country, on the basis of current scientific knowledge.</span></font></p>
        <p><font size="3"><span lang="EN-US">Couples known to be at increased genetic risk on the
        basis of their family history, age, or results of screening tests, often limit further
        reproduction when family planning is available, and need guaranteed access to family
        planning services. In theory, when average family size is large restriction to two or
        three children could reduce the birth prevalence of major single gene disorders by 40-50%.
        When final family size is small there is proportionately less effect. However, there is no
        good observational data from developing countries. </span></font></p>
        <p style="page-break-after:avoid"><font size="3"><span lang="EN-US">Information obtained
        through the proposed WHO initiative on parental age distribution, and effects of genetic
        counselling after the diagnosis of an affected child, will permit calculation of such
        effects on a national and global scale.</span></font></p>
        <p style="page-break-after:auto"><font size="3"><a name="_Toc496677293"></a><strong><a
        name="3.2 &nbsp; Optimizing women's diet"><span lang="EN-US">3.2 &nbsp; Optimizing
        women's diet</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Women of reproductive age need an adequate diet.
        There is growing evidence that maternal health and nutrition can affect the
        childrens' predisposition to the common non-communicable diseases whose prevalence is
        increasing in the adult population of most developing countries. For example maternal
        malnutrition is related to low birth weight, which in turn is related to an increased risk
        of ischaemic heart disease and non-insulin-dependent diabetes mellitus in the offspring,
        while maternal anaemia appears to increase the risk of hypertension (21). As the
        mother's pre-pregnancy status appears to affect these outcomes, it is important to
        prevent maternal anaemia and malnutrition before, as well as during pregnancy. Because it
        is not easy to identify a pre-conception period with certainty, women should have an
        adequate diet throughout the reproductive span. In principle this means a diet that is
        adequate in terms of energy and of micronutrients such as iron, iodine and vitamins.
        However, the evidence from randomized trials for a beneficial effect on the fetus is
        rather unsatisfactory, the effects of multi-vitamin and folate supplementation being the
        best documented (22).</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.2.1&nbsp; Protein/calorie nutrition </span></font></strong></p>
        <p><font size="3"><span lang="EN-US">A Cochrane review of randomized studies of providing
        malnourished women with nutritional supplements of energy (usually with protein) during
        pregnancy (23) reported that balanced protein/energy supplementation resulted in modest
        increases in maternal weight gain and fetal growth, with more effect when the energy
        content of the supplement was very high. It also seemed to reduce the risk of stillbirth
        and neonatal death. There was no evidence of larger benefits for undernourished women, or
        of long-term improvements in the child's growth or neurocognitive development, and
        there was inadequate evidence to evaluate effects on preterm birth or maternal health.</span></font></p>
        <p><font size="3"><span lang="EN-US">The apparent inconsistency between these results and
        the work mentioned above may be due to the relative insensitivity of the outcomes used,
        the likelihood that supplementation is more effective if started prior to pregnancy, and
        the inability of such studies to assess long-term outcomes. Studies of supplementation
        prior to pregnancy, or other approaches for assessing the long-term effects of maternal
        (mal)nutrition in developing countries are needed.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.2.2&nbsp; Dietary folate </span></font></strong></p>
        <p><font size="3"><span lang="EN-US">Neural tube defects fall into the category of
        multifactorial disorders, with both genetic and environmental factors involved in their
        genesis. In Western populations, an increased risk of having an affected child is
        associated with altered maternal homocysteine metabolism and reduced folate levels,
        related to a 677 C to T polymorphism in the methyltetrahydrofolate reductase (MTHFR) gene.
        Randomized controlled trials in countries with a high birth prevalence of neural tube
        defects have shown that supplementing women's diet with folate prior to and in the
        first months after conception reduces the risk of fetal neural tube defect (22). No
        adverse effects of folate supplementation have been detected, apart from a possible small
        increase in multiple pregnancies. Multivitamins themselves did not have any observed
        effect, either alone or when given in addition to folate. The daily folate intake
        necessary for full protection is considered to be about 0.4 mg/daily, but the average
        (western) diet contains only half this amount (22). Folate supplementation starting at
        least two months before conception is therefore now recommended in most western countries.
        In China folate supplementation has been found to have more effect in the north than the
        south, possibly reflecting better nutrition in the south (24). Since women cannot always
        foresee a pregnancy, and it is difficult to ingest enough folate with usual Western diets,
        folate fortification of common foodstuffs may be indicated. &nbsp; This has recently been
        implemented in the United States. Data on the effect of the policy on prevalence of neural
        tube defects is now awaited.<o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">Should dietary folate supplementation be universally
        recommended? Experience from South Africa shows that Western experience cannot be presumed
        to apply elsewhere (25). Firstly, the common predisposing MTHFR mutation is rare in black
        South Africans. Secondly, there is evidence of lower folate status in urban black South
        African women than in their rural counterparts, but paradoxically the urban birth
        prevalence of infants with neural tube defects is low, at 0.55 - 1.64 /1,000, while birth
        prevalences of 3.55 and 6.13/1000 have been recorded in rural populations. In this
        population therefore, an assumption that the problem would respond to folate
        supplementation could be misleading, and further research is needed before implementing
        recommendations for prevention in this setting.</span></font></p>
        <p><font size="3"><span lang="EN-US">In conclusion, quality baseline data is needed on
        birth prevalence of neural tube defects in every population where folate supplementation
        is considered. Ideally, evidence should also be sought on the prevalence of the MTHFR and
        other possible polymorphisms, folate content of the diet, blood folate status and
        homocysteine metabolism.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.2.3&nbsp; Iodine deficiency</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">Severe iodine deficiency in the mother can lead to
        impaired fetal brain development, and is probably the most important cause of mental
        retardation in arid or mountainous areas where iodine deficiently is prevalent (26). The
        current global campaign to prevent iodine deficiency by iodination of salt is likely to
        lead to a significant reduction in such mental handicap. Further information on this
        subject should be collected at the WHO level, and by the national task force in each
        country participating in the WHO initiative.<o:p></o:p></span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.2.4&nbsp; Iron deficiency</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">This is extremely common in pregnant women and in
        children in less developed countries (27). In principle, it should be corrected because
        haemoglobin level is directly related to physical energy i.e. there is evidence that
        infants of iron-deficient mothers have reduced iron stores, and iron deficiency causes a
        measurable, persistent reduction of IQ in children (28). Iron supplementation of basic
        foodstuffs, or providing children with iron-supplemented biscuits is therefore recommended
        in some countries (29).</span></font></p>
        <p><font size="3"><span lang="EN-US">A Cochrane review of randomized studies in more
        developed countries (30) showed that iron supplementation for pregnant women with an
        initial haemoglobin level below 10 g/dl reduces anaemia in late pregnancy, but no
        detectable effect on maternal hypertension or infection, preterm or post term delivery,
        low birthweight or admission to a neonatal unit was observed. One trial showed a reduced
        likelihood of caesarean section and post-partum blood transfusion, but more stillbirths
        (possibly related to increased blood viscosity related to high haemoglobin) in the
        routinely supplemented group. Therefore, in developed countries the tendency is to suggest
        selective rather than routine iron supplementation.</span></font></p>
        <p><font size="3"><span lang="EN-US">The indication that routine iron supplementation may
        reduce the need for post-partum- blood transfusion could be important where there is a
        need to avoid blood transfusions. Otherwise these studies have little relevance for
        communities where iron deficiency is common and anaemia in pregnancy is a serious health
        problem, because the most important outcomes are long-term effects on the physical and
        mental development and health of the child, and the woman's physical ability to cope
        with her family. There is practically no information from less developed countries on the
        effect of iron supplementation in pregnancy on these outcomes. This important health issue
        could be adopted as special sub-study within the planned WHO initiative.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.2.5&nbsp; Alcohol consumption and smoking</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">It is not yet possible to definitely identify a safe
        limit of alcohol consumption during pregnancy. Moderate alcohol consumption during the
        first trimester of pregnancy&nbsp; (two or more drinks per week to two drinks per day)
        involves little if any additional risk of fetal malformation, but this might not apply for
        effects on intellectual development.</span></font></p>
        <p><font size="3"><span lang="EN-US">The effect of alcohol is likely to be continuous and
        dose related, starting with a healthy child and ending with the full blown fetal alcohol
        syndrome, including learning difficulties, poor growth, and sometimes congenital
        abnormalities involving the face, limbs, heart and nervous system (31). Unfortunately,
        there is a high recurrence rate of fetal alcohol syndrome in subsequent pregnancies. As
        with neural tube defects, polymorphisms influencing rate and route of alcohol metabolism
        occur with different prevalence in different populations, so population differences in
        susceptibility to fetal alcohol syndrome may be anticipated. Studies from wine-growing
        areas in South Africa showing an extremely high prevalence of fetal alcohol syndrome (32)
        suggest that this should be carefully studied in other areas with a significant alcohol
        producing industry.</span></font></p>
        <p><font size="3"><span lang="EN-US">There is no convincing evidence that smoking
        significantly increases the risk of congenital malformations, though there may be a small
        increase in prevalence of cleft lip with or without cleft palate. It does increase the
        chance of miscarriage, bleeding in pregnancy, premature birth, and sudden infant death
        syndrome (33). Stopping smoking in early pregnancy reduces these risks, and up to a
        quarter of women who smoke stop before their first antenatal visit.</span></font></p>
        <p><strong><font size="3"><a name="3.3&nbsp; Managing maternal health problems"><span
        lang="EN-US">3.3&nbsp; Managing maternal health problems</span></a></font></strong></p>
        <p><font size="3"><span lang="EN-US">Women with insulin dependent diabetes have
        approximately a 6% risk of a seriously malformed child in each pregnancy (34). The risk
        can be greatly reduced by meticulous control of the blood sugar, but this must be started
        before pregnancy, because major malformations are already present by five weeks
        post-conception (35). Appropriate advice for women, and assistance in achieving the
        necessary standard of blood sugar control should be a routine part of diabetes care.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.3.1&nbsp; Epilepsy during pregnancy</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">It is not possible to discontinue anti-epileptic
        drugs during pregnancy, as uncontrolled seizures can affect the fetus as well as the
        mother. However, care must be taken to ensure that doses are the lowest necessary for
        seizure control. The four commonly used anticonvulsants (phenytoin, carbamazepine, sodium
        valproate and phenobarbitone) convey a significant teratogenic risk, but more than 90% of
        women who receive these drugs during pregnancy deliver a baby free of birth defects (36).</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.3.2&nbsp; Treatment of malaria during
        pregnancy</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">This is particularly relevant in many less developed
        countries. There is no evidence to suggest that any antimalarial drugs are teratogenic at
        standard dosages, and standard doses of quinine do not increase the risk of abortion or
        preterm delivery (37). Primaquine is not recommended because of the potential risk of
        intravascular haemolysis in a G6PD deficient fetus, but there is no evidence of an
        increased risk of kernicterus in the newborn following intrauterine exposure to
        antimalarial drugs containing sulphonamides or sulphones. <o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">Information on the safety of doxycycline,
        halofantrine, and artemisinin derivatives in pregnancy is currently limited.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.3.3&nbsp; Maternal inherited disorders</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">People with serious inherited conditions are
        increasingly surviving to reproductive age because of improved medical care. It is
        important for them to be diagnosed and have access to appropriate pregnancy care. For
        example in sickle cell disorder an increased risk of sickle cell crisis can be fatal for
        the pregnant woman (38), while in thalassaemia there is an increased risk of stillbirth
        unless the mother is adequately transfused throughout pregnancy (39). A mother with
        phenylketonuria requires excellent dietary control throughout pregnancy because
        phenylalanine crosses the placenta, and a raised level in the mother causes mental
        retardation in the child even if their genotype is normal (40).</span></font></p>
        <p><font size="3"><a name="_Toc496677295"></a><strong><a
        name="3.4&nbsp; Avoiding maternal infections"><span lang="EN-US">3.4&nbsp; Avoiding
        maternal infections</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">It is essential to diagnose maternal infections in
        order to reduce the risk of vertical transmission or teratogenesis:</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.4.1&nbsp; Human immunodeficiency virus
        (HIV) infection</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">This is the major cause of congenital infection in
        the developing world. Over one million children had been infected from their mother by the
        end of 1998. The risk of mother-to-child transmission appears to be 15-20% in Europe,
        15-30% in USA and 25-35% in Africa.</span></font></p>
        <p><font size="3"><span lang="EN-US">A number of strategies employed to reduce the risk of
        fetal infection have been assessed in randomized trials (41):</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Treatment with zidovudine appears to be safe in pregnancy. It significantly reduces risk
        of mother-to-child transmission at any dose, independently of whether the mother breast
        feeds, and decreases risk of stillbirth and infant death. Preliminary findings suggest a
        further decrease in risk when zidovudine is combined with lamivudine in the antenatal and
        intrapartum period, or the intrapartum and postpartum period (42). However, these drugs
        are too costly for widespread use in the developing countries that need them most.
        Unfortunately there is no evidence of reduced transmission when combination therapy is
        given only at delivery.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elective
        caesarian section may decrease mother-to-child transmission by 50% - though its widespread
        use in less developed countries is also unrealistic. Disinfecting of the vagina prior to
        and/or during labour, and avoidance of artificial rupture of the membranes may reduce
        transmission, and could be adopted widely.<o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast
        feeding may double the risk of mother-to-child transmission of HIV, but WHO recommends
        that HIV infected women should avoid breast feeding only if they have access to resources
        for safe artificial feeding.</span></font></p>
        <p><font size="3"><span lang="EN-US">Randomized trials are in progress in developing
        countries, to evaluate vaginal cleansing, vitamin and nutritional supplementation and
        breast versus artificial feeding. In addition nevirapine (a new long-acting
        anti-retroviral drug) requires urgent evaluation, to assess the benefit of a single dose
        in labour followed by a single dose to the neonate.</span></font></p>
        <p><font size="3"><span lang="EN-US">Once again, the first step in dealing with maternal
        transmission of HIV infection is to know the prevalence of the condition in the
        population, so that an appropriate strategy can be developed. The problem to be overcome
        here is the reluctance of some ministries and governments to acknowledge the true extent
        of the problem. Everything that has been said about early action to prevent congenital
        disorders applies even more strongly for HIV (e.g. with early recognition of the problem,
        it may be possible to afford treatment for pregnant women, but this may become impossible
        if infection becomes more common). Further information on this topic should be collected
        by liaison with the WHO AIDS programme.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.4.2&nbsp; Rubella infection</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">This infection is common world-wide, and is highly
        teratogenic. In many countries rubella is now included in childhood immunization
        programmes, and pregnant women are routinely screened to confirm their immune status.
        Intra-uterine death or congenital malformations due to rubella infection of the fetus, and
        congenital rubella have become extremely rare in these areas (43). The limited information
        available for less developed countries indicates that though the majority of girls may be
        immune by the time they reach reproductive age, congenital rubella syndrome still occurs
        (10). It is important to establish the proportion of non-immune adult women in relation to
        age in participating countries, in order to develop the most appropriate prevention
        strategy.</span></font></p>
        <p><font size="3"><span lang="EN-US">It is considered that rubella immunization should be
        included in the expanded immunization programme only if over 90% coverage can be achieved
        and sustained. This is because immunization interrupts natural transmission during
        childhood and coverage of less than 90% creates a pool of non-immune women with the risk
        of a future epidemic and an increase in congenital rubella syndrome. In the absence of
        universal immunization alternative strategies may be adopted. For example, immunization
        may be offered to schoolgirls. In countries where a premarital medical consultation is
        usual, women may be screened and those not already immune may be immunized. Failing that,
        women may be tested during pregnancy, and those not immune immunized after the baby is
        born.<o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">Data is needed for each country on women's'
        age-related immunity to rubella, in order to select an appropriate approach.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.4.3&nbsp; Syphilis</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">In females primary syphilis is often asymptomatic and
        as natural immunity does not eliminate the organism, an infected woman can transmit
        infection in every pregnancy. There is a considerable increase in the chance of a
        stillbirth or neonatal death, and about 20% of&nbsp; surviving infants later develop
        congenital infection. Congenital syphilis is entirely preventable if infected women are
        detected during pregnancy and treated with penicillin before fetal damage has occurred,
        and is now extremely rare where screening for anti-treponema antibodies is routine in
        antenatal care. However, this is not the case in many less developed countries. Statistics
        are needed on the prevalence of this avoidable cause of congenital disorders.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">3.4.4&nbsp; Toxoplasmosis and other maternal
        infections</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">Toxoplasma gondii is a protozoan intracellular
        parasite that can be transmitted to the fetus and cause mental retardation, congenital
        blindness, or later onset blindness in humans. Though it is found in many animals, spore
        production occurs only in the intestine of the cat. Humans may become infected through
        contact with cat faeces or raw meat, or by eating under-cooked meat. Infection in
        pregnancy is usually asymptomatic, but leads to overt or latent infection of the fetus in
        about 10% of cases. Overt infection can cause miscarriage, neonatal disease, or severe
        ocular problems. Latent infection may become reactivated in childhood, leading to damage
        to the eye or brain. The effect of diagnosis during pregnancy and treatment with
        spiramycin in avoiding congenital abnormalities is still under review (44). However, risk
        of infection can be reduced by advising pregnant women to avoid contact with cat faeces,
        wash their hands carefully after handling raw meat, and cook meat carefully, and these
        simple steps may be promoted to all pregnant women. The risk of listeriosis may be reduced
        similarly by avoiding certain foodstuffs. Information is needed from less developed
        countries on the prevalence of herpes simplex infection and other maternal infections with
        implications for the fetus. </span></font></p>
        <p><font size="3"><span lang="EN-US">Diagnosis of infections in the newborn requires a
        skilled pathologist: the role of the perinatal pathologist is discussed below.</span></font></p>
        <p><font size="3"><a name="_Toc496677296"></a><strong><a
        name="3.5&nbsp; Implementation of basic reproductive health approaches"><span lang="EN-US">3.5&nbsp;
        Implementation of basic reproductive health approaches</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">The primary objective of the proposed WHO initiative
        is to help couples to achieve a healthy family by preventing avoidable congenital
        disorders, as well as improving the survival and quality of life of those affected by
        them. In order to reach the entire population of reproductive age the initiative must be
        based in primary care, and health workers in primary care and reproductive health need
        appropriate training and clearly written guidelines.</span></font></p>
        <p><font size="3"><span lang="EN-US">Ideally, health workers should ensure that women have
        the following information before their first pregnancy:</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        The risk of miscarriage and of fetal chromosomal abnormality rises with maternal age.
        Risks can be reduced by family planning.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Diet should be adequate in calories, iodine, vitamins (including folate) and iron, before
        as well as during pregnancy.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        It is important for women to know their Rhesus blood group.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        It is important for women to be immune to rubella.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Risk of infection with toxoplasma or Listeria can and should be avoided.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Smoking, alcohol, and medications for specific disorders can increase the risk of
        miscarriage, congenital abnormality and fetal growth retardation.</span></font></p>
        <p
        style="margin-top:0cm;margin-right:-2.9pt;margin-bottom:
6.0pt;margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font
        size="3"><span lang="EN-US">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        (When available) genetic counselling may be helpful for families with a history of
        repeated abortions, stillbirth, perinatal, infant and childhood death, congenital
        malformations, and inherited disorders.</span></font></p>
        <p style="margin-left:1.0cm;text-indent:-1.0cm;mso-list:l16 level1 lfo14"><font size="3"><span
        lang="EN-US">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        (When available) carrier testing is advisable for specific common genetic risks (e.g.
        haemoglobin disorders).</span></font></p>
        <p><font size="3"><span lang="EN-US">Each national task force should design appropriate
        training packages for health workers: this is also an&nbsp; essential step towards an
        informed population. Educational requirements are addressed more fully below.</span></font></p>
        <p style="margin-left:36.0pt;text-indent:-36.0pt"><font size="3"><a name="_Toc496677297"></a><strong><a
        name="4.&nbsp; Screening for increased risk of congenital disorders"><span lang="EN-US">4.&nbsp;
        Screening for increased risk of congenital disorders</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Implementation of the above basic reproductive health
        approaches can reduce the birth prevalence of infants with serious congenital disorders to
        a baseline level. Further reduction requires population screening programmes, aiming to
        identify and inform individuals at increased risk of having children with specific
        disorders. </span></font></p>
        <p><font size="3"><a name="_Toc496677298"></a><strong><a
        name="4.1&nbsp; General ethical principles of genetic population screening"><span
        lang="EN-US">4.1&nbsp; General ethical principles of genetic population screening</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Screening programmes target specific groups of
        conditions, and aim to reach the whole community. The support of the public health
        authorities is essential, and approaches must be adapted to the local health
        infrastructure. </span></font></p>
        <p><font size="3"><span lang="EN-US">Recognized requirements for population screening are
        as follows (46):</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
        target condition should be common, or a serious though less common problem.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Screening should be able to lead to a clear diagnosis in the majority of cases.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
        natural history of the condition should be well enough understood to permit prediction of
        outcomes.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There
        should be an effective and acceptable management strategy (treatment and/or prevention).</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
        programme should be cost-effective.</span></font></p>
        <p><font size="3"><span lang="EN-US">The predictive nature of population screening calls
        for the highest possible standard of diagnosis, quality control, information and
        counselling. On the other hand, the service must be delivered by large numbers of health
        workers with little pre-existing education in genetic diagnosis or counselling, to a
        population that is usually unaware of any increased risk. Genetic population screening
        should therefore be planned, executed and monitored systematically, and plans must include
        appropriate resources for education and training for health professionals and for the
        provision of information to the public.</span></font></p>
        <p><font size="3"><span lang="EN-US">The indications for and feasibility of different
        types of screening differ by country: each screening service should be introduced as a
        research project within the local medical and social context.</span></font></p>
        <p><font size="3"><span lang="EN-US">Screening for risk of inherited disorders in
        offspring can be done at any time of life. It should ideally be offered prior to
        pregnancy, so that individuals and couples at risk can choose from the fullest range of
        available options.</span></font></p>
        <p><font size="3"><span lang="EN-US">Screening for increased risk of sporadic conditions
        such as congenital malformations and chromosomal disorders is possible only during
        pregnancy, and can be provided within a national health service only when termination of
        pregnancy on medical grounds is accepted practice. (However, when ultrasound is used
        during pregnancy major malformations are inevitably diagnosed, and obstetricians cannot
        avoid decisions on what to offer the parents.)</span></font></p>
        <p><font size="3"><span lang="EN-US">When screening can lead to abortion, every effort
        should be made to offer screening as early as possible in order to reduce social
        difficulties, ethical conflicts, suffering and medical risks to the lowest level possible.
        In practice, in many developing countries genetic abortion is permitted only in the first
        trimester of pregnancy. </span></font></p>
        <p align="left" style="margin-left:35.25pt;text-align:left;text-indent:-35.25pt"><font
        size="3"><a name="_Toc496677299"></a><strong><a
        name="4.2&nbsp; Antenatal ultrasound screening for congenital malformations"><span
        lang="EN-US">4.2&nbsp; Antenatal ultrasound screening for congenital malformations</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Fetal anomaly scanning is the most powerful approach
        available for reducing the birth prevalence of infants with serious congenital
        abnormalities, and increasing the chance of survival for those who are born. The finding
        of a correctable abnormality can be an indication for delivery to take place at a centre
        with facilities for paediatric surgery: the finding of a severe uncorrectable abnormality
        may lead to the offer of termination of pregnancy:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fetal
        anomaly scanning is most sensitive at around 19 weeks' gestation, when 40-70% of
        major malformations can be detected by a trained operator (47).</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Possibilities for detecting severe malformations in the first trimester of pregnancy are
        increasing, with availability of more powerful machines and vaginal probes. For example
        with appropriate training most neural tube defects, and major cardiac anomalies can be
        detected from around 13 weeks gestation (48). </span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Increasing experience has shown an association between chromosomal anomalies and
        ultrasound markers, including the shape of the ventricles at 19 weeks and increased nuchal
        translucency at 11 weeks (49). The indications for offering fetal karyotyping on the
        grounds of these findings are the subject of much current research.</span></font></p>
        <p><font size="3"><span lang="EN-US">Fetal anomaly scanning is a highly expert procedure
        and it is, therefore, generally recommended to be introduced in two distinct stages.
        Initially, it may be offered as a specialist service to women at recognized high risk
        (older women, those with diabetes or epilepsy, or a previous child with a congenital
        disorder, consanguineous couples). This arrangement permits the development of local
        expertise, training and audit, while the high frequency of abnormalities maintains
        operators' alertness and minimizes risk of error. The offer of fetal anomaly scanning
        to all pregnant women is a move to population screening, and should be seen as distinct
        second step. In particular, even with standardized training, routine scanning by less
        expert operators greatly increases the risk of false positives (leading potentially to
        abortion of healthy fetuses) and false negatives (because abnormalities are rare and
        alertness may be reduced). The high level of expertise required, and the serious
        implications of false positives and false negatives for both families and health services
        must be taken into account in planning programmes and in obtaining informed consent.</span></font></p>
        <p><font size="3"><span lang="EN-US">Falling prices are making ultrasound equipment
        increasingly available world-wide - e.g. in Egypt it is planned to provide machines at
        district health centres. When there is ready access to ultrasound examination in the
        public or the private sector, routine fetal anomaly scanning is likely to be offered. The
        following were, therefore, strongly recommended by the expert group:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Accreditation of ultrasound operators at different levels of expertise.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use of
        standardized protocols.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Referral
        to a recognized expert centre when an abnormality is suspected.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Mandatory registration of all abortions on the ground of fetal abnormality.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Mandatory confirmation of the prenatal diagnosis by post-mortem examination of the aborted
        fetus. Full autopsy is desirable but not essential, as much information can be gained
        through a standardized non-invasive post mortem examination including external physical
        examination, clinical photographs, X-ray of the fetus, search for infections, chromosome
        analysis of the skin and or blood, and DNA banking when possible (50).</span></font></p>
        <p><font size="3"><span lang="EN-US">Each national task group needs to define the training
        and accreditation of ultrasound operators who will participate in the planned
        interventions. The national task group should include a member with expertise in perinatal
        pathology, who can train others and ensure that a standardized protocol appropriate for
        the country situation is followed.</span></font></p>
        <p><font size="3"><a name="_Toc496677300"></a><strong><a
        name="4.3&nbsp; Antenatal screening for chromosomal disorders"><span lang="EN-US">4.3&nbsp;
        Antenatal screening for chromosomal disorders</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">For antenatal detection of chromosomal disorders,
        karyotyping is done on material obtained in the first trimester by chorionic villus
        sampling (CVS), or in the second by amniocentesis, fetal blood sampling or CVS. When a
        serious abnormality is found, termination of pregnancy is offered. In theory the
        proportion of Down syndrome births that can be prevented in this way depends on:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
        proportion of mothers over 35-37 years of age at conception.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
        efficiency with which younger women at increased risk can be detected.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
        acceptability of prenatal diagnosis and selective abortion to the population.</span></font></p>
        <p><font size="3"><span lang="EN-US">In practice, additional and crucial limiting factors
        are (a) the limited capacity of cytogenetic laboratories, (b) ignorance among primary care
        workers about whom to refer, when karyotyping is available, and (c) the fact that in many
        developing countries only first trimester diagnosis is considered acceptable. In each
        participating country the national task group should identify a policy for most
        cost-effective use of scarce laboratory resources, in the light of these considerations.</span></font></p>
        <p><font size="3"><span lang="EN-US">Usually the first step is to offer fetal karyotyping
        to known high-risk groups - older women, and those who have already had an affected child.
        This approach has the advantage of permitting first trimester diagnosis by chorionic
        villus sampling.</span></font></p>
        <p><font size="3"><span lang="EN-US">Risk of Down syndrome in younger women is presently
        assessed in Western countries by complex mid-trimester serum screening methods, an
        approach that is unsuitable for most developing countries, and will probably soon be
        superseded. Risk assessment using ultrasound indicators such as fetal nuchal translucency
        requires careful standardized training of ultrasound operators. However, it permits first
        trimester diagnosis by chorionic villus sampling and so could be an appropriate approach
        in many developing countries.</span></font></p>
        <p><span lang="EN-US"><font size="3">It is also necessary to consider the most
        cost-efficient laboratory techniques for developing countries: first trimester diagnosis
        by karyoptyping of chorionic villus material is more complex than diagnosis using cells
        obtained by mid-trimester amniocentesis.</font></span></p>
        <p><font size="3"><a name="_Toc496677301"></a><strong><a
        name="4.4&nbsp; Identifying increased risk of inherited disorders"><span lang="EN-US">4.4&nbsp;
        Identifying increased risk of inherited disorders</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">People who may develop an inherited disorder
        themselves or pass one on to their children may be identified either by family studies
        starting with an affected individual, or by population screening, or both. The diagnosis
        of an affected individual, or a carrier, has implications for the whole family. Everyone
        with a definitive genetic diagnosis or known to be at increased risk needs information and
        counselling. </span></font></p>
        <p><font size="3"><span lang="EN-US">Figure 3 shows the intimate relationship between the
        dual objectives of screening, best possible patient care and information and choice for
        those at risk. For every genetic diagnosis, information is needed on the implications for
        the person's own health, for their partner and children, and for other blood
        relatives. It is not possible to deal with a person with a genetic diagnosis as an
        isolated individual, or to focus on one objective or pathway of a genetic screening
        programme to the exclusion of the others.</span></font></p>
        <p><strong><font size="3"><span lang="EN-GB">Figure 3.&nbsp; </span><span lang="EN-US">Diagram
        showing the types of information and care pathways needed<br>
        by people with a genetic diagnosis</span></font></strong></p>
        <p
        style="margin-top:0cm;margin-right:-.05pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt"><font
        size="2"><span lang="EN-GB"><!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75"
 style='width:344.25pt;height:258pt' o:ole="">
 <v:imagedata src="file:///C:/TEMP/msoclip1/01/clip_image003.wmz" o:title=""/>
</v:shape><![endif]--><img src="clip_image004.gif" v:shapes="_x0000_i1026" width="459" height="344"><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PowerPoint.Slide.7" ShapeID="_x0000_i1026"
  DrawAspect="Content" ObjectID="_1037171370">
 </o:OLEObject>
</xml><![endif]--><o:p></o:p></span></font></p>
        <p style="margin-left:14.2pt"><font size="3"><span lang="EN-GB">The pathways apply for all
        genetic diagnoses, whether of carrier or affected, and whether predictive or diagnostic. A
        person with a genetic diagnosis is nested within a family group, itself nested within
        wider society. Hence individuals cannot be treated in isolation, and information and care
        pathways cannot be insulated from each other. (TOP = termination of pregnancy.)<o:p></o:p></span></font></p>
        <p><strong><font size="3"><span lang="EN-US">4.4.1&nbsp; Use of the family history </span></font></strong></p>
        <p><font size="3"><span lang="EN-US">When a person is found to suffer from, or to carry an
        inherited disorder, they (or, in the case of children, their parents) should be informed
        of the implications for their own health, for the health of their possible children, and
        for other blood relatives. A health worker should collaborate with them (or their parents)
        in identifying and informing family members who could be at risk, so that they can be
        informed and offer testing when appropriate. The family history is a very powerful tool
        for early detection of people at risk for dominant and X-linked disorders (e.g. familial
        cancers), and is an important indicator of increased risk for multifactorial conditions
        such as coronary heart disease or hypertension. When consanguineous marriage is common it
        is also a powerful tool for detecting carriers of recessively inherited disorders like
        cystic fibrosis, thalassaemia and sickle cell disorders (see below). However, the extent
        to which family studies are carried out in practice in developed countries is limited by
        availability of trained health workers, facilities for definitive diagnosis, and the
        context in which the diagnosis is made.</span></font></p>
        <p><font size="3"><span lang="EN-US">The family history can also be seen as a screening
        tool for scanning the general population for people at risk for a wide range of inherited
        disorders and genetic predispositions. To exploit this possibility a standardized method
        for taking a basic genetic family history in primary care and reproductive health
        services, and appropriate training packages are needed. </span></font></p>
        <p><strong><font size="3"><span lang="EN-US">4.4.2&nbsp; Population screening for carriers
        of inherited disorders</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">When an inherited condition is common and serious and
        carriers can be reliably detected, it may be appropriate to offer genetic screening to the
        whole population. The by now extensive experience of population screening for carriers of
        Tay-Sachs disease or haemoglobin disorders provides a general model for genetic population
        screening programmes, and should be reviewed by each national task group. There is as yet
        limited practical experience of screening for cystic fibrosis (51, 52).</span></font></p>
        <p><font size="3"><span lang="EN-US">Figure 4 shows the fall in the birth rate of children
        with a major thalassaemia in four countries where screening is standard practice, and
        national audit data is available (14-17). </span></font></p>
        <p><strong><font size="3"><span lang="EN-US">Figure 4.&nbsp; Fall in the birth rate of
        children with thalassaemia major in three <br>
        countries where audit data is available (Based on ref 12, updated.)</span></font></strong></p>
        <p align="center" style="text-align:center;page-break-after:avoid"><font size="2"><span
        lang="EN-US"><!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75"
 style='width:395.25pt;height:252.75pt' fillcolor="window">
 <v:imagedata src="file:///C:/TEMP/msoclip1/01/clip_image005.wmz" o:title=""/>
</v:shape><![endif]--><img src="clip_image006.gif" v:shapes="_x0000_i1027" width="527" height="337"><o:p></o:p></span></font></p>
        <p><font size="3"><span lang="EN-US">The most marked fall has been in Cyprus, Italy and
        Greece where national programmes promote premarital screening, most at risk couples are
        identified in time for the offer of prenatal diagnosis in the first pregnancy, and the
        majority use this service to obtain a healthy family. The lower (50%) fall in the UK
        reflects problems in service delivery, rather than lack of interest on the part of
        potential parents (17). The absence of a national policy leads to geographically uneven
        service delivery, while carrier screening only in the context of pregnancy care leads to
        late identification of risk, lack of continuity of care from one pregnancy to the next,
        and failure to provide family information and counselling. The UK data clearly demonstrate
        the need for policies aiming to identify all at risk couples in time for counselling
        before or early in their first pregnancy, and to involve primary health care as well as
        reproductive health services.</span></font></p>
        <p><font size="3"><span lang="EN-US">Sickle cell disorders are more unpredictable than
        thalassaemias, and counselling is correspondingly more complex (53). Many affected
        individuals have a good quality of life, and in some parts of the world (Eastern Saudi
        Arabia, Bahrain, India) additional genetic factors reduce the severity of the disorder.
        Neonatal diagnosis is recommended because simple protective measures including information
        for the parents, prophylactic penicillin and antimalarial treatment, provide a high degree
        of protection for affected children (54). Though most at risk couples would like to know
        the diagnosis in the fetus, many decline prenatal diagnosis because of the risk to the
        pregnancy. Uptake is higher in the first than the second trimester, and more couples
        decide to continue an affected pregnancy than is the case with thalassaemia (53).</span></font></p>
        <p><font size="3"><a name="_Toc496677302"></a><strong><a
        name="4.5&nbsp; Genetic counselling and consanguineous marriage"><span lang="EN-US">4.5&nbsp;
        Genetic counselling and consanguineous marriage</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">The focus of genetic counselling for consanguineous
        marriage is on risk of recessively inherited disorders, as marriage pattern has no known
        effect on the prevalence of other congenital disorders (10). In populations where
        consanguineous marriage is common, studies of the extended family of affected children (or
        healthy carriers) might be the appropriate approach, because family members are not only
        at particularly high risk, but are also likely to have personal experience of the target
        condition (10, 55).</span></font></p>
        <p><font size="3"><span lang="EN-US">This approach has been tested for thalassaemia in
        Pakistan, where carrier prevalence is approximately 5% and prenatal diagnosis is available
        (56). In this situation, with random mating 1 in 400 couples would be at risk and
        approximately one at risk couple would be identified per 420 people screened. In the
        extended family study 30% of family members tested were carriers, and one at risk couple
        was found for every 32 individuals tested. Unmarried carriers were also informed of their
        carrier status and its implications. Follow-up studies are planned on the effect of
        partner choice and reproductive behaviour (Dr Suhaib Ahmed, in preparation).</span></font></p>
        <p><font size="3"><span lang="EN-US">Further work is obviously needed, but the findings
        suggest that extended family studies, though labour-intensive, offer a highly
        cost-effective approach for risk detection in such populations. The approach also has the
        great advantage of being equally valid for rare and for common conditions - providing
        carriers can be detected. Recent advances in genetic science are increasing the
        feasibility of carrier detection and simplifying the laboratory techniques required.</span></font></p>
        <p><font size="3"><a name="_Toc496677303"></a><strong><a
        name="4.6&nbsp; Avoiding morbidity and mortality due to neonatal jaundice"><span
        lang="EN-US">4.6&nbsp; Avoiding morbidity and mortality due to neonatal jaundice</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Neonatal jaundice is a multifactorial condition which
        can cause death or severe life-long disability if untreated. Preventable genetic causes
        include Rhesus incompatibility between mother and fetus, and glucose-6-phosphate
        dehydrogenase (G6PD) deficiency in the newborn.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">Table 7.&nbsp; Average prevalence of Rhesus
        negativity, and genetic and clinical implications, in different parts of the world</span></font></strong></p>
        <table border="1" width="98%" height="390">
          <tr>
            <td width="11%" height="105"><font size="2"><span lang="EN-US">Region<o:p></o:p></span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US"><br>
            d gene frequency<o:p></o:p></span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US"><br>
            % of population Rh -ve<o:p></o:p></span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US">% of Rh -ve women with Rh
            +ve partner</span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US"><br>
            % of women alloimmunised<br>
            <a style="mso-footnote-id:ftn1" href="#_ftn1" name="_ftnref1" title>[1]</a><o:p></o:p></span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US">Potential severe
            problems&nbsp; due to Rh negativity / 1000<a style="mso-footnote-id:ftn2" href="#_ftn2"
            name="_ftnref2" title>[2]</a><o:p></o:p></span></font></td>
            <td width="11%" height="105"><font size="2"><span lang="EN-US">Rh -ve women, % of partners
            Dd or DD<o:p></o:p></span></font></td>
            <td width="10%" height="105"><font size="2"><span lang="EN-US">Rh -ve women, % of fetuses
            dD<o:p></o:p></span></font></td>
            <td width="13%" height="105"><font size="2"><span lang="EN-US">Rh -ve women, % chance of
            becoming isoimmunised<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">N Europe<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.45<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">20.3<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">16.1<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">1.13<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">5.4<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">80<o:p></o:p></span></font></td>
            <td width="10%" height="21"><font size="2"><span lang="EN-US">55.0<o:p></o:p></span></font></td>
            <td width="13%" height="21"><font size="2"><span lang="EN-US">6<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">N Europe, S Europe <o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.35<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">12.3<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">10.7<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.75<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">3.6<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">88<o:p></o:p></span></font></td>
            <td width="10%" height="38"><font size="2"><span lang="EN-US">65.0<o:p></o:p></span></font></td>
            <td width="13%" height="38"><font size="2"><span lang="EN-US">7<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">N Africa, Middle East<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.3<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">9.0<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">8.2<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.57<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">2.8<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">91<o:p></o:p></span></font></td>
            <td width="10%" height="38"><font size="2"><span lang="EN-US">70.0<o:p></o:p></span></font></td>
            <td width="13%" height="38"><font size="2"><span lang="EN-US">7.5<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">W Africa, Middle East<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.25</span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">6.3<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">5.9<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">0.41<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">2.0<o:p></o:p></span></font></td>
            <td width="11%" height="38"><font size="2"><span lang="EN-US">94<o:p></o:p></span></font></td>
            <td width="10%" height="38"><font size="2"><span lang="EN-US">75.0<o:p></o:p></span></font></td>
            <td width="13%" height="38"><font size="2"><span lang="EN-US">8.1<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">N India &amp; Pakistan</span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">0.2</span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">4.0<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">3.8<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">0.27<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">1.3<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">96<o:p></o:p></span></font></td>
            <td width="10%" height="36"><font size="2"><span lang="EN-US">80.0</span></font></td>
            <td width="13%" height="36"><font size="2"><span lang="EN-US">8.6</span></font></td>
          </tr>
          <tr>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">Sub-Saharan Africa</span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">0.1<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">1.0<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">1.0<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">0.07<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">0.3<o:p></o:p></span></font></td>
            <td width="11%" height="36"><font size="2"><span lang="EN-US">99<o:p></o:p></span></font></td>
            <td width="10%" height="36"><font size="2"><span lang="EN-US">90.0<o:p></o:p></span></font></td>
            <td width="13%" height="36"><font size="2"><span lang="EN-US">9.7<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">China and SE Asia max<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.05</span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.3<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.2</span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.017<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.08<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">99.8<o:p></o:p></span></font></td>
            <td width="10%" height="21"><font size="2"><span lang="EN-US">95.0</span></font></td>
            <td width="13%" height="21"><font size="2"><span lang="EN-US">10.2<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">China and SE Asia min</span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.01<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.0<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.01<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.0007<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">0.003<o:p></o:p></span></font></td>
            <td width="11%" height="21"><font size="2"><span lang="EN-US">99.99<o:p></o:p></span></font></td>
            <td width="10%" height="21"><font size="2"><span lang="EN-US">99.0</span></font></td>
            <td width="13%" height="21"><font size="2"><span lang="EN-US">10.7<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p><font size="2"><span lang="EN-US"><o:p><a style="mso-footnote-id:ftn1" href="#_ftnref1"
        name="_ftn1" title>[1]</a> Estimated 7% of Rh negative with incompatible partner become
        alloimmunized.</span></font></p>
        <p><font size="2"><span lang="EN-US"><a style="mso-footnote-id:ftn2" href="#_ftnref2"
        name="_ftn2" title>[2]</a> Severe problems - stillbirth, neonatal death or kernicterus due
        to Rh alloimmunization.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">4.6.1&nbsp; Rhesus incompatibility</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">In a Rhesus negative woman, alloimmunisation by red
        cells from a Rhesus positive fetus (or Rhesus positive blood transfusion) can cause
        hydrops fetalis in subsequent pregnancies, or kernicterus in the newborn. The prevalence
        of Rhesus negativity differs widely in different parts of the world (Table 7), and the
        risk to a Rhesus negative woman of having a Rhesus&nbsp; incompatible fetus, and becoming
        alloimmunised, increases with falling prevalence.</span></font></p>
        <p><font size="3"><span lang="EN-US">Administration of anti-D immunoglobulin to Rhesus
        negative women after childbirth, miscarriage or abortion reduces the risk of
        alloimmunisation by more than 95%. Policies for prevention (according to prevalence and
        available resources) range from giving anti D postpartum only to Rhesus negative women
        with a Rhesus positive partner and an ABO-compatible newborn, to giving all Rhesus
        negative women two prophylactic doses during pregnancy, plus one dose within 72 hours of
        birth (57). </span></font></p>
        <p><font size="3"><span lang="EN-US">Data is needed for each country on the proportion of
        Rhesus negative women who become alloimmunised, on the present practice in screening for
        Rhesus blood group and antibodies during pregnancy, and on the availability and cost of
        anti-D immunoglobulin.</span></font></p>
        <p><font size="3"><span lang="EN-US"><strong>4.6.2&nbsp; Glucose-6-phosphate dehydrogenase
        (G6PD) deficiency</strong> </span></font></p>
        <p><font size="3"><span lang="EN-US">G6PD deficiency is a common predisposing factor for
        severe neonatal jaundice. It can also lead to life-threatening acute haemolytic anaemia
        following consumption of a limited range of common medications or fava (broad) beans (58).
        In areas where fava beans are a common basic food, as in the Mediterranean area, parts of
        the Middle East Iran and southern China, G6PD deficiency is responsible for seasonal waves
        of favism among young children. Neonatal screening for G6PD deficient infants, and
        informing their parents and primary care workers of the increased risk, can greatly reduce
        the incidence of these complications. In some countries screening for risk of neonatal
        jaundice is considered unnecessary because all jaundiced infants are routinely diagnosed
        and appropriately managed, but the risk of favism remains. This can be greatly reduced by
        public education - for example in Cyprus, hospital admissions for favism declined abruptly
        following a campaign advising parents to avoid giving fresh broad beans to children,
        especially boys (Dr M Angastiniotis, personal communication).</span></font></p>
        <p><font size="3"><span lang="EN-US">Programmes of neonatal screening for G6PD deficiency
        and advice for parents are now established in parts of South East Asia, such as Singapore
        and Malaysia, where G6PD deficiency is common, the usual mutation is severe, and
        haemolysis is exacerbated by environmental factors including contact with baby clothes
        stored with moth-balls, or presence in breast milk of components of herbal remedies taken
        by the mother (18). Parents are advised to ensure that G6PD-deficient newborn children are
        exposed to light and to avoid storing baby clothes with naphathalene-containing
        preparations. Later in life they should avoid fresh fava beans, and medications that can
        precipitate a haemolytic crisis. </span></font></p>
        <p><font size="3"><span lang="EN-US">There is a serious lack of reliable information on
        the health burden of G6PD deficiency for use in health service planning, especially from
        Africa. Information is needed from each participating country on prevalence of G6PD
        deficiency and neonatal jaundice, and the proportion of children with neurological and
        learning disorders (possible sequelae of severe neonatal jaundice) who have G6PD
        deficiency. Data on the effectiveness of existing screening programmes should also be
        reported.</span></font></p>
        <p><font size="3"><a name="_Toc496677304"></a><strong><a
        name="4.7 &nbsp; Neonatal screening"><span lang="EN-US">4.7 &nbsp; Neonatal screening</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Neonatal screening involves organized examination of
        new-borns in order to diagnose specific disorders and provide appropriate treatment, as
        far as possible. It includes both clinical and laboratory approaches.</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">4.7.1&nbsp; Clinical neonatal screening</span></font></strong></p>
        <p><font size="3"><span lang="EN-US">All live-born babies should be examined
        systematically for congenital malformations by a doctor or a trained nurse using a
        checklist. The neonatal examination is a key element in the proposed WHO study, where all
        abnormalities detected will be confirmed by a paediatrician, and registered for
        epidemiological purposes. An agreed standardized protocol for neonatal examination is
        needed. Attachment 2 includes some conditions that can be diagnosed by careful neonatal
        examination, with relatively simple interventions possible at the primary health care
        level. Randomized studies have cast serious doubt on the safety and efficacy of neonatal
        screening for congenital dislocation of the hip using the Ortolani-Barlow manoeuvre, which
        has long been standard practice in developed countries. This will not form part of the WHO
        initiative.</span></font></p>
        <p><font size="3"><span lang="EN-US">Early identification of congenital deafness followed
        by appropriate intervention avoids difficulties in speech acquisition and promotes
        integration of deaf children into society. A careful UK review of the benefits and
        efficacy of deafness screening in infancy identified neonatal testing using automated
        evocation of auditory brainstem response as the most cost-effective approach (59). It can
        be used selectively for infants in high-risk groups (who have been in intensive care,
        suffered a neonatal infection or have a family history of deafness), but universal
        screening was recommended as the most cost-effective approach. Since recessive inheritance
        is a particularly important in profound deafness, neonatal screening for congenital
        deafness could be particularly valuable in countries where consanguineous marriage is
        common. The report, which includes a detailed assessment of costs, should be reviewed by
        the national task group of participating countries.</span></font></p>
        <p><font size="3"><span lang="EN-US">All stillborn infants or infants dying in the
        perinatal period should have a post mortem examination, performed by a trained person.
        This is an important element in the WHO study. Since full autopsy is unacceptable in many
        societies and is not available in many countries, a standardized agreed protocol for
        non-invasive perinatal post-mortem examination will be required for the WHO study (50).</span></font></p>
        <p><strong><font size="3"><span lang="EN-US">4.7.2&nbsp; Biochemical neonatal screening </span></font></strong></p>
        <p><font size="3"><span lang="EN-US">Neonatal screening for phenylketonuria, congenital
        hypothyroidism, sickle cell disorders and G6PD deficiency meet the criteria for a
        screening service in many countries. In most developed countries, a midwife or nurse
        routinely takes heel-prick blood samples onto a filter paper (Guthrie) card at 5-10 days
        after birth, and posts it to a central newborn screening laboratory. The system was
        introduced in the 1960s for phenylketonuria, because a low phenylalanine diet prevents
        severe mental retardation if started in the first weeks of life. The feasibility of
        implementing routine neonatal screening depends on the health care and communications
        infrastructure, but once it has been set up for one condition, it is relatively simple to
        add screening for other conditions, and to carry out epidemiological research. </span></font></p>
        <p><font size="3"><span lang="EN-US">The cost benefit equation of neonatal screening needs
        careful evaluation in each country, in the light of the prevalence of each disorder and
        local priorities. For example, testing for phenylketonuria is cheap but the diet is
        expensive, can be difficult to obtain, and is not completely effective. By contrast,
        screening for congenital hypothyroidism is relatively expensive, but thyroxine treatment
        is easy, cheap and completely effective. In addition, samples may be needed at different
        times for different diagnoses: cord blood samples taken at birth can be used for screening
        for sickle cell disorders or G6PD deficiency, while screening for metabolic disorders
        should be done at the very earliest at 48 hours after birth, to allow the baby's
        metabolism to stabilize sufficiently for reliable results. </span></font></p>
        <p><font size="3"><span lang="EN-US">There is growing recognition that inherited metabolic
        disorders can be a significant cause of neonatal and infant death, and that they are
        particularly important in populations with a high prevalence of consanguineous marriage
        (60). A wide range of these disorders can now be diagnosed on dried Guthrie blood spots
        using tandem mass spectrometry, and the case for introducing this form of screening in
        developed countries has been reviewed (61). </span></font></p>
        <p><font size="3"><a name="_Toc496677305"></a><strong><a
        name="4.8 &nbsp; The timing of population screening"><span lang="EN-US">4.8 &nbsp; The
        timing of population screening</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">A basic requirement in population screening is a
        &#147;turnstile&#148; - an appropriate point at which the relevant population routinely
        comes into contact with the health system and can be offered screening. Three common
        turnstiles are marriage, onset of pregnancy, and birth.</span></font></p>
        <p><font size="3"><span lang="EN-US">Table 8 shows the optimal timing for the
        interventions and screening procedures discussed above (10).</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 7.1pt 14.2pt"><strong><font size="3"><span
        lang="EN-US">Table 8.&nbsp; Optimal timing in reproductive life of the recommended<br>
        preventive interventions </span></font></strong></p>
        <table border="1" width="100%">
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Desirable prior to pregnancy<o:p></o:p></span></font></td>
            <td width="33%"><font size="2"><span lang="EN-US">Feasible only during pregnancy<o:p></o:p></span></font></td>
            <td width="34%"><font size="2"><span lang="EN-US">Feasible only neonatally<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Family planning<o:p></o:p></span></font></td>
            <td width="33%"><font size="2"><span lang="EN-US">Ultrasound screening for congenital
            malformations</span></font></td>
            <td width="34%"><font size="2"><span lang="EN-US">Clinical examination for congenital
            abnormalities<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Advice on women's diet<o:p></o:p></span></font></td>
            <td width="33%"><font size="2"><span lang="EN-US">Screening for risk of chromosomal
            disorders</span></font></td>
            <td width="34%"><font size="2"><span lang="EN-US">Biochemical screening <o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Appropriate management of maternal
            disorders e.g. diabetes<o:p></o:p></span></font></td>
            <td width="33%"><font size="2"><span lang="EN-US">Diagnosis and treatment of maternal
            infections<br style="mso-special-character:line-break">
            </span></font></td>
            <td width="34%">&nbsp;</td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Avoiding infections by immunization and
            precautions</span></font></td>
            <td width="33%">&nbsp;</td>
            <td width="34%">&nbsp;</td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Screening for Rh blood group</span></font></td>
            <td width="33%">&nbsp;</td>
            <td width="34%">&nbsp;</td>
          </tr>
          <tr>
            <td width="33%"><font size="2"><span lang="EN-US">Screening for risk of inherited
            disorders<o:p></o:p></span></font></td>
            <td width="33%">&nbsp;</td>
            <td width="34%">&nbsp;</td>
          </tr>
        </table>
        <p><font size="3"><span lang="EN-US">In countries where most couples marry before starting
        a family, a premarital medical consultation can provide an ideal opportunity for
        pre-pregnancy advice. However this does not apply in many countries (e.g in Western
        Europe), and screening is often offered only when women attend for antenatal care. This
        greatly reduces the impact of interventions aiming to reduce fetal abnormality.&nbsp; For
        example:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Information on the importance of folate and other nutrients reaches mothers too late in
        pregnancy to be useful.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Pre-pregnancy testing for maternal infection, pre-pregnancy treatment and immunization are
        not possible. This applies for rubella, hepatitis, syphilis, tetanus, and also for HIV.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of
        inherited disorders may be detected only in the second trimester. Since late abortion is
        unacceptable to many couples, uptake of prenatal diagnosis is lower than with earlier risk
        identification (17, 53).</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is
        no chance to ensure optimal control of maternal insulin-dependent diabetes prior to
        conception.</span></font></p>
        <p><font size="3"><span lang="EN-US">Admittedly, information obtained during the first
        pregnancy may be used in subsequent pregnancies, but when fertility is low this is a very
        ineffective approach. </span></font></p>
        <p><font size="3"><span lang="EN-US">In countries where premarital screening and
        counselling is not an option another pre-pregnancy turnstile must be found. The
        feasibility of integrating genetic screening and counselling into family planning services
        should be investigated in a range of settings.</span></font></p>
        <p><font size="3"><span lang="EN-US">Each participating country needs to review the
        optimal timing for providing information and testing, and identify an approach that will
        permit pre-pregnancy information and counselling, as far as possible. The chosen policy
        will determine the pattern of health workers involved, and their educational and training
        needs.</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><a name="_Toc496677306"></a><strong><a
        name="4.9&nbsp; Education for health workers, and information for the public"><span
        lang="EN-US">4.9&nbsp; Education for health workers, and information for the public</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">The educational task required when a new programme is
        introduced into a health service may be analyzed as follows:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Description of the aims of, and evidence base for the intervention.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis
        of tasks and activities involved, allocation of each to the appropriate level of the
        health system, and identification of the appropriate health workers.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Definition of the knowledge, attitude and skills required for each task, the means for
        imparting them, and the training time required.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decision
        on whether and how training fits into existing courses, and where training time will come
        from.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Development of curricula and full supporting training materials for each category of
        health worker.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decision
        on method and frequency of data collection, and preparation of relevant supporting systems
        (forms, software, etc).</span></font></p>
        <p><font size="3"><span lang="EN-US">No comprehensive model is available for this
        substantial programme of work. The services that exist in more developed countries have
        grown up in an ad hoc and unrelated manner, so though they offer examples of good practice
        they are not seen as components of a single discipline. For the purposes of the WHO
        initiative it is necessary to identify examples, bring them into a systematic
        relationship, develop an outline curriculum and training materials and make these widely
        available.</span></font></p>
        <p><font size="3"><span lang="EN-US">Similarly, the important issue of information for the
        public has been relatively neglected, even though information is a key component in
        medical genetic interventions. Available examples of methods for imparting appropriate
        knowledge about genetics to the public should also be collected and reviewed. </span></font></p>
        <p><font size="3"><a name="_Toc496677307"></a><strong><a
        name="5. &nbsp; The WHO initiative"><span lang="EN-US">5. &nbsp; The WHO initiative</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">Despite significant gaps in knowledge, existing
        evidence shows an urgent and growing need for systematic national and international
        initiatives aiming to reduce the health burden of congenital and genetic disorders. This
        proposal for a WHO programme on the control of congenital and genetic disorders in primary
        health care is a major new initiative, designed in response to increasing global demand.
        It was originally initiated at a meeting of a Working Group convened at the Eastern
        Mediterranean Regional Office of WHO in November 1995 and elaborated further at the Cairo
        meeting of December 1999.&nbsp; There is as yet no existing model that can be implemented
        at the country level, and a long-term programme including substantial research and
        development is required.</span></font></p>
        <p><font size="3"><span lang="EN-US">Because of wide differences between countries, the
        appropriate approach is to implement a programme of work intended to support an organized
        approach to the control of congenital disorders in any setting. The proposed programme of
        work has three distinct phases: development of a country plan, execution of a
        demonstration project implementing selected interventions, and countrywide implementation.
        </span></font></p>
        <p><font size="3"><span lang="EN-US">The approach is recommended for consideration to all
        countries. Implementation within a collaborative international study with WHO technical
        support is foreseen for selected countries. The following steps are proposed for
        participating countries. </span></font></p>
        <p><font size="3"><a name="_Toc496677308"></a><strong><a
        name="5.1 &nbsp; Formation of a national task force"><span lang="EN-US">5.1 &nbsp;
        Formation of a national task force</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">A national (or local) multi-disciplinary task force
        should be convened to review the local epidemiology and health burden of congenital and
        genetic disorders and identify priority areas for intervention. The long-term aim of the
        task force is to define and monitor national policy on control of congenital and genetic
        disorders.</span></font></p>
        <p><font size="3"><span lang="EN-US">The task force should include representatives of the
        Ministry of Health (and relevant professional associations), specialists in e.g.
        epidemiology, statistics, informatics, paediatrics, genetics, pathology, haematology,
        obstetrics, maternal and child health and primary care, laboratory experts in
        biochemistry, cytogenetics and molecular medicine.</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 21.3pt"><font size="3"><span lang="EN-US">The task
        force needs a coordinator. This person must have certain characteristics, e.g. must be
        highly motivated, understand the principles of genetics and public health, be familiar
        with local health services, and have a collaborative outlook, facilitating working with
        professional colleagues. Their chief responsibilities should be coordinating
        evidence-based decision-making, organizing the programme, carrying out evaluation, and
        providing information at all levels. They should have the position, training and technical
        and clerical support required to perform these duties.</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 21.3pt"><font size="3"><span lang="EN-US">The task
        group coordinator will require skills in paediatric and/or reproductive medicine, medical
        genetics, public health, epidemiology, education and information technology. No recognized
        training course exists to fit individuals for this role. Many necessary skills may be
        obtained through collaboration with the WHO task group, and training country
        representatives should be seen as one of its principal tasks. The WHO should also
        encourage governments to arrange individually tailored training for the country
        coordinator in areas where it is needed. </span></font></p>
        <p><font size="3"><a name="_Toc496677309"></a><strong><a
        name="5.2 &nbsp; Development of a national plan"><span lang="EN-US">5.2 &nbsp; Development
        of a national plan</span></a></strong></font></p>
        <p style="margin-bottom:3.0pt"><font size="3"><span lang="EN-US">The first task for the
        task force is to produce a country report, in standardize format (to be developed). The
        report should contain:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Description of the organization of primary health care and reproductive health services
        (which differ greatly by country).</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basic
        demographic data, by administrative and ethnic subdivisions of the population.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A
        summary of available data on the local frequency and causes of congenital disorders.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An
        assessment of the resources available for the initiative.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A plan
        for a pilot of the proposed epidemiological study.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Referral
        pathways for patients, and families thought to be at risk.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Recommended approaches for surveillance of congenital disorders.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Issues
        surrounding acceptability of prenatal diagnosis and genetic abortion at different stages
        of pregnancy.</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 21.3pt"><font size="3"><span lang="EN-US">The task
        force will then develop a draft national plan taking account of:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local
        priorities.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        realistic approaches, in the light of local resources and cultural conventions.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible
        &#147;entry points&#148; for a programme.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether
        programmes should be vertical or integrated.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether
        it is best to start with a single issue, or whether a more general approach should be
        adopted from the outset.</span></font></p>
        <p style="tab-stops:-72.0pt -36.0pt 21.3pt"><font size="3"><span lang="EN-US">Every
        national plan should promote both best possible patient care and appropriate approaches
        for prevention.</span></font></p>
        <p align="left" style="margin-left:35.25pt;text-align:left;text-indent:-35.25pt"><font
        size="3"><a name="_Toc496677310"></a><strong><a
        name="5.3 &nbsp; The baseline epidemiological study (the WHO mother and baby study)"><span
        lang="EN-US">5.3 &nbsp; The baseline epidemiological study (the WHO mother and baby study)</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">The epidemiological study is intended to generate
        reliable data to support planning, and to set up some systems (e.g. for education and
        audit) that are required for the proposed demonstration project, and for national
        implementation (Attachments I and II).</span></font></p>
        <p><font size="3"><span lang="EN-US">The epidemiological study will&nbsp; be conducted
        using standardized methods in facilities where babies are born, in the area where the
        demonstration project will be conducted. The draft protocol is given in Attachment I. It
        includes a core study with optional components: </span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A target
        population of at least 15,000 recently delivered women will be interviewed to obtain
        information on their demographic background and obstetric history. Previous stillbirths
        and deaths will be included. Attachment I includes data collection sheets for mother and
        the baby. These are intended only to show the data that should be collected. They need not
        be used in the study, as duplication must be avoided. When the required data is already
        collected in standard antenatal records, these may be photocopied. If existing antenatal
        records do not include all the necessary data, they may be modified for the study and
        photocopied. Alternatively, the forms in Attachment I may be used.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whether
        the outcome of the current pregnancy is a live- or stillbirth or a neonatal death, the
        baby will be examined and the findings recorded using a standard checklist for examination
        of the newborn (see baby data collection sheet 1 - screening examination). If a congenital
        anomaly is suspected in a liveborn baby this will be noted, and the baby will be examined
        by a specialist&nbsp; member of the study team, where available. The findings and
        provisional diagnosis will be recorded (see baby data collection sheet 2 - live baby with
        congenital anomaly), using a checklist. Special attention should be directed to ensuring
        that babies in intensive care are included.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is a
        priority to examine all stillborn babies and those that die in the neonatal period, in the
        target population. Wherever possible, an expert will examine each baby and the
        observations recorded (see baby data collection sheet 2 - stillbirth or neonatal death).
        Standard photographs and whole body X-rays may be taken, and added to the record. Reports
        (or copies) of intra-uterine, pre-mortem or post-mortem ultrasound examinations may be
        included. An autopsy may not be feasible, but blood or tissue samples may be taken for
        tests relevant to diagnosis, to provide information on which to base counselling for the
        parents. If no diagnosis is made, a parent may be asked if samples can be stored for
        future testing, in the event of relevant diagnostic tests becoming available.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As an
        optional study, blood samples will be collected from the mother, agreed haematological
        tests will be conducted, and serum separated, labeled and stored. Blood tests will be
        carried out using methods locally available and chosen by the research team. A discussion
        of selected methods is to be included in the manual of operations. It is a priority to
        ensure quality control.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As an
        optional study, blood samples from all babies will be collected onto Guthrie cards and
        forwarded to the study centre, or a designated laboratory, for selected investigations.
        Guthrie cards for study later will be sealed in plastic envelopes and stored in a metal
        box in a cool environment. A special effort will be made to include a sample from each
        dead baby: in this case blood may be taken by cardiac puncture.</span></font></p>
        <p><font size="3"><span lang="EN-US">All records will be forwarded to the national study
        team. They will be checked, coded and entered on the database by staff of the study team.
        Any uncertainties or incompleteness in data collection will be corrected as soon as
        possible by liaison with the staff at the place of birth.</span></font></p>
        <p><font size="3"><span lang="EN-US">Initial coding of disorders detected in mothers and
        infants will use ICD10. Where possible, abnormalities will be coded by the specialist
        doctor undertaking the diagnostic examination. In addition to basic ICD10 coding they will
        use McKusick (OMIM) codes, as these are more detailed than ICD10 in recording congenital
        anomalies.</span></font></p>
        <p><font size="3"><span lang="EN-US">Parents of all stillborn babies, of liveborn babies
        with a congenital disorder diagnosed at birth or later, and all carriers of inherited
        disorders diagnosed in the course of the study will be referred for expert counselling on
        steps they can take to reduce (recurrence) risks.</span></font></p>
        <p><font size="3"><span lang="EN-US">The status of all data will be reviewed at regular
        meetings of the study team.</span></font></p>
        <p><font size="3"><a name="_Toc496677311"></a><strong><a
        name="5.4 &nbsp; The intervention study (demonstration project)"><span lang="EN-US">5.4
        &nbsp; The intervention study (demonstration project)</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">It is too early to make detailed plans for the
        demonstration intervention project that is the final objective of this WHO initiative. The
        epidemiological study will provide the data needed for planning, and offers an opportunity
        for developing and testing instruments, creating primary care training packages, and
        establishing methods for monitoring process and outcomes.</span></font></p>
        <p><font size="3"><a name="_Toc496677312"></a><strong><a name="6. &nbsp; The role of WHO"><span
        lang="EN-US">6. &nbsp; The role of WHO</span></a></strong></font></p>
        <p><font size="3"><span lang="EN-US">It is appropriate for WHO to take the lead in this
        important global initiative, including seeking support from relevant international
        organizations and donors.</span></font></p>
        <p><font size="3"><span lang="EN-US">The WHO human genetics and reproductive health
        programmes should collaborate in:</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; defining
        and assessing the health burden related to congenital disorders.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        identifying evidence-based interventions, and examples of good practice.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        identifying realistic priorities for countries at different stages of development, and
        with different health systems.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; guiding
        the process of national policy development and service planning.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        providing training packages and electronic tools.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        establishing and applying methods for surveillance.</span></font></p>
        <p><font size="3"><span lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        providing long-term support for task forces in interested countries.</span></font></p>
        <p><font size="3"><span lang="EN-US">The first step is to commission a collaboration
        between selected experts and relevant WHO programmes, including human genetics,
        reproductive health, primary health care, iodine supplementation, AIDS etc. The aim should
        be to draw on existing experience to update knowledge of the global epidemiology and
        health burden of congenital and genetic disorders. A standard format for describing
        epidemiology and health burden should be developed for supporting health service planning
        in any country. </span></font></p>
        <p><font size="3"><span lang="EN-US">This collaboration will form the basis for a WHO
        multi-disciplinary task force, bringing representatives of WHO programmes and appropriate
        experts into a long-term working relationship. Corresponding multidisciplinary groups
        should be created at the WHO regional level. The WHO task force should collaborate with
        representatives of participating countries in the following programme of work:</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Improving information on
        epidemiology and health burden. Existing data should be reviewed in the light of its
        relevance to congenital and genetic disorders, gaps should be identified, and plans made
        to fill them. For example, information is needed on:</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iodine deficiency: prevalence in
        pregnancy, and likely effects of the current prevention programme on maternal and child
        health. </span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iron deficiency: prevalence in
        pregnancy, and likely effects of supplementation on maternal and child health.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infectious diseases: prevalence
        of HIV, syphilis and rubella in pregnancy, including age-related data on immunity to
        rubella in order to select the appropriate approach for immunization.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhesus blood group: the
        proportion of Rhesus negative women who become alloimmunised, and present practice in
        screening and prevention of alloimmunisation.</span></font></p>
        <p style="margin-left:32.15pt;tab-stops:-72.0pt -36.0pt list 32.15pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; G6PD deficiency: role in
        neonatal jaundice and its sequelae, prevalence of acute haemolysis, and data on existing
        neonatal screening programmes.</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Review recommended
        interventions and new evidence-based developments (e.g. in neonatal deafness screening).</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agree standard methods and
        finalize protocols for:</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinical examination of the
        newborn.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-invasive perinatal
        post-mortem examination. </span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taking a basic genetic family
        history.</span></font></p>
        <p style="text-indent:0cm;mso-list:none;tab-stops:-72.0pt -36.0pt"><font size="3"><span
        lang="EN-US">&nbsp;<o:p></o:p></span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Identify cost-effective
        approaches for:</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cost-effective use of scarce
        laboratory resources.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tracking prevalence of iron
        deficiency at the population level.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; identifying genetic risk, e.g.
        extended family studies versus screening.</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agree training, education
        and accreditation requirements:</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for country coordinators. This
        is crucially important for the success of the initiative: see page 29.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; identify feasible approaches for
        deploying the recommended interventions using existing health care infrastructures.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; identify the health workers
        involved, and their educational and training needs.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; review existing training
        courses.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop an outline curriculum,
        and appropriate training packages for health workers, and disseminate them appropriately.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agree required training and
        accreditation of ultrasound operators.</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collaborate on developing
        appropriate information materials for patients and the public:</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; set up an information/education
        task group.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; review existing information
        resources, and agree on basic information and standards.</span></font></p>
        <p style="margin-left:36.0pt;tab-stops:-72.0pt -36.0pt list 36.0pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; examine the value of a global
        approach to standardizing, translating, and disseminating quality information: consider
        IT-based approaches.</span></font></p>
        <p
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:l8 level1 lfo35;
tab-stops:-72.0pt -36.0pt list 18.0pt"><font
        size="3"><span lang="EN-US">7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research: organize
        international research studies on: </span></font></p>
        <p style="margin-left:32.2pt;tab-stops:-72.0pt -36.0pt list 32.2pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; birth prevalence of infants with
        metabolic disorders using tandem mass spectrometry examination of Guthrie blood spots.</span></font></p>
        <p style="margin-left:32.2pt;tab-stops:-72.0pt -36.0pt list 32.2pt"><font size="3"><span
        lang="EN-US">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; short and long-term effects of
        iron supplementation in pregnancy on the health of mother and child.</span></font></p>
        <p><font size="3"><span lang="EN-US">Interested countries should recruit a national task
        group and start collecting background data for a country report and country plan, without
        delay. The WHO task group will recommend a format for and comment on country reports,
        check the design of pilot studies and be responsible for the design of the baseline
        epidemiological study, and methods for recording and analyzing results. They will ensure
        standardization of all recommended tests and procedures, and co-operate with participating
        countries in producing training packages, first for the epidemiological study, and later
        for the intervention study. The WHO task force group will be ultimately responsible for
        programme surveillance, and assessment of the impact of the interventions on national and
        global health burden.</span></font></p>
        <span lang="EN-US"><p></span>&nbsp;</p>
        <p><font size="3"><a name="_Toc496677313"></a><strong><a name="List of Participants"><span
        lang="EN-US">List of Participants</span></a></strong></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr O.O.
        Akinyanju, Professor of Medicine, College of Medicine, University of Lagos, P.M.B. 12003,
        Lagos, Nigeria [fax: +234 1 618 778;&nbsp; e-mail: oluphysic@cyberspace.net.ng]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr. Shaikha
        Al-Arrayed, Chief, Genetics Unit, P.O.Box 12, Manama, Bahrain [fax: 00973&nbsp;
        275612/689959]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr W. Anwar,
        Director General, Technical Department, Ministry of Health, Cairo, Egypt <o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr P. Baird,
        Professor of Medical Genetics, University of British Columbia, 222-6174 University Blvd.,
        Vancouver, British Columbia, V6T 1Z3, Canada [fax: 604 822 3565;&nbsp; e-mail:
        pbaird@interchange.ubc.ca]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr J.M. Cantú
        Garza, Chief, Genetics Division, Centro de Investigación Biomédica de Occidente,
        Instituto Mexicana del Seguro Social, Siena No. 1068 Lomas de Providencia, Guadalajara,
        Jalisco, Mexico [fax: +523 6188 069;&nbsp; e-mail: jmcantu@koch.mb.udg.mx]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr J. Chapple,
        Consultant, Kensington &amp; Chelsea and Westminster Health Authority, 50 Eastbourne
        Terrace, London W2 6LX, UK [Fax: 0044 171 281 8004;&nbsp; e-mail:
        jean.chapple@HA.kcw-ha.nthames.nhs.uk]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Professor A.L.
        Christianson, Head, Department of Human Genetics and Developmental Biology, Faculty of
        Medicine, University of Pretoria, P.O. Box 667, Pretoria 0001, South Africa [fax: +27 12
        323 2788;&nbsp; e-mail: christal@medic.up.ac.za]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Mr M. Darlison,
        &nbsp; WHO Collaborating Centre on the Control of Hereditary Disease, RF &amp; UC Medical
        School, Department of Primary Care &amp; Population Sciences, Holborn Union Building,
        Archway Campus, Highgate Hill, London N19 3UA, UK [Fax: 0044 171 281 8004;&nbsp; e-mail
        m.darlison@ ucl.ac.uk]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr N. Firdous,
        Consultant, Ministry of Health, Maldives, c/o WR, &nbsp;&nbsp;Maldives [fax: 00960 32
        2221;&nbsp; e-mail: she8804@dhivehinet.net.mv] (unable to attend)</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr L. Heredero,
        Director, Centro Nacional de Genética Médica, Calle 31 esquina a 146, Cubanacan, Playa,
        Havana, Cuba [e-mail: lhere@infomed.sld.cu]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Huang
        Shangzhi, Director, Department of Medical Genetics, Institute of Basic Medical Sciences,
        Chinese Academy of Medical Sciences 5, Dong Dan San Tiao, Beijing 100005, China [fax: 0086
        10 65229323; e-mail: huangsz@263.net]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Lim Nyok
        Ling, Consultant, Dept. of Paediatrics, Hospital Selayang, Lebuhraya Selayang-Kepong,
        68100 Batu Caves, Selangor, Malaysia [fax 03 613 77097 &#150; tel. 03 613 7788, ext. 5050;
        e-mail: drchin@tm.net.my]<o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr M. Modell,
        Consultant, Department of Primary Care &amp; Population Sciences, Holborn Union Building,
        Archway Campus, Highgate Hill, London N19 3UA, UK [Fax: 0044 171 281 8004; e-mail:
        m.modell@ucl.ac.uk]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr E. Abdel
        Saalam, Professor of Paediatrics &amp; Genetics, Cairo University, Cairo, Egypt <o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Ashraf
        Samavat, Ministry of Health and Medical Education Under Secretary of Health, Disease
        Control &amp; Prevention Department, South Iranshahr Avenue, Tehran, Islamic Republic of
        Iran [Fax: 009821 830444]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Kamel
        Shadpour, Senior Expert, Primary Health Care Department, Ministry of Health and Medical
        Education, Tehran Islamic Republic of Iran</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Ishwar Verma,
        Head, Department of Medical Genetics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi
        110060, India [fax: +91 11 685 4434; e-mail: icverma@giasdL01.vsnL.net.in]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Pornswan
        Wasant, Chief of Genetics, Department of Pediatrics, Faculty of Medicine, Siriraj
        Hospital, Mahidol University, Bangkok, 10700, Thailand [fax: +662 419-8414;&nbsp; e-mail:
        sipws@mahidol.ac.th</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">&nbsp;<o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">WHO/HQ <o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr A. Alwan,
        Director,&nbsp; Division of Noncommunicable Disease Prevention,
        CH-1211&nbsp;Geneva&nbsp;27, Switzerland [fax: +41 22 791 4259;&nbsp; e-mail:
        alwana@who.ch]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Mrs G.
        Bellevaux, Human Genetics, Division of Noncommunicable Disease Prevention,
        CH-1211&nbsp;Geneva&nbsp;27, Switzerland [fax: +41 22 791 47 69;&nbsp; e-mail:
        bellevauxg@who.ch]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr V.
        Boulyjenkov, Human Genetics, Division of Noncommunicable Disease Prevention,
        CH-1211&nbsp;Geneva&nbsp;27, Switzerland [fax:+41 22 791 47 69; e-mail:
        boulyjenkovv@who.ch] (Secretary) </span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr B. Modell,
        WHO Consultant, Head of the WHO Collaborating Centre on the Control of Hereditary Disease,
        RF &amp; UC Medical School Department of Primary Care &amp; Population Sciences, Holborn
        Union Building, Archway Campus, Highgate Hill, London N19 3UA, UK [Fax: 0044 171 281
        8004;&nbsp; e-mail: b.modell@ucl.ac.uk] <o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Q.M. Islam,
        Reproductive Health and Research, WHO, CH-1211 Geneva 27<br>
        [Fax: +41 22 791 4189; e-mail: islamm@who.ch]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">&nbsp;<o:p></o:p></span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">WHO/EMRO</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Hussein A.
        Gezairy,&nbsp; Regional Director, WHO Office for the Eastern Mediterranean, P.O. Box 1517,
        Alexandria 21511, Egypt [Tel. 203 48 202 23;&nbsp; fax 203 48 38 916]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr Z. Hallaj,
        WHO Representative, Magles el Shab Street, Cairo, Egypt [Tel. +202 355 3708: e-mail:
        wregypt@intouch.com]</span></font></p>
        <p align="left" style="text-align:left"><font size="3"><span lang="EN-US">Dr K. Al Roomi,
        Consultant, WHO Regional Office for the Eastern Mediterranean, Alexandria, Egypt</span></font></p>
        <span lang="EN-US"><p></span>&nbsp;</p>
        <p><font size="3"><a name="_Toc496677314"></a><strong><a name="References"><span
        lang="EN-US">References</span></a></strong></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Nations
        Demographic Yearbook series. United Nations, New York.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baird PA,
        Anderson TW, Newcombe HB, Lowry RB. 1988. Genetic disorders in children and young adults:
        a population study. American Journal of Human Genetics 42: 677-693.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baird PA. 1999.
        Prenatal screening and the reduction of birth defects in populations. Community Genetics
        2: 9-17.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; De Wals P,
        Weatherall JAC, Lechat MF. Registration of Congenital anomalies in Eurocat centres 1979 -
        1983. An EEC Concerted Action Project. Cabay 1985.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Christianson AL.
        Down syndrome in sub Saharan Africa. 1996. Journal of Medical Genetics 33: 89-92.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHO 1994.
        Guidelines for control of haemoglobin disorders. Unpublished document of the WHO.
        WHO/HDP/HB/GL/94.1. Updated global epidemiological data available at
        www.chime.ucl.ac.uk/APoGI/</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHO 1985.
        Glucose-6-Phosphate Dehydrogenase Deficiency. Report of a WHO Working Group. Unpublished
        WHO Document HDP/WP/G6PD/85.9.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bittles AH.
        1990. Consanguineous marriage: current global incidence and its relevance to demographic
        research. Population studies center, University of Michigan. Research report no 90-186.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Modell B, Kuliev
        AM, Wagner M. Community Genetics Services in Europe. WHO Regional Publications, European
        Series No 38. WHO Regional Office for Europe, 8 Scherfigsvej, DK-2100, Copenhagen,
        Denmark. 1992.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">10.&nbsp;&nbsp;&nbsp; Alwan AA, Modell B. Community Control of
        Genetic and Congenital Disorders. EMRO Technical Publications Series 24. World Health
        Organization Regional Office for the Eastern Mediterranean. 1997.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">11.&nbsp;&nbsp;&nbsp; Costa T, Scriver C, Childs B. 1985. The
        effect of Mendelian disease on human health: A measurement. American Journal of Medical
        Genetics 21: 231-242.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">12.&nbsp;&nbsp;&nbsp; Zeuner D, Ades AE, Karnon J, Brown J,
        Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK:
        review and economic analysis. NHS R&amp;D HTA Programme. 1999. ISSN 1366-5278. (Full text
        available at www.hta.nhsweb.nhs.uk)</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">13.&nbsp;&nbsp;&nbsp; Hoffbrand AV, Wonke B. 1997. Iron
        chelation therapy. Journal of Internal Medicine 242 (Supplement 740): 17-41.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">14.&nbsp;&nbsp;&nbsp; Loukopoulos D. 1996. Current status of
        thalassaemia and the sickle cell syndromes in Greece. Seminars in Hematology 33: 76-86.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">15.&nbsp;&nbsp;&nbsp; Cao A. Results of programmes for
        antenatal detection of thalassaemia in reducing the incidence of the disorder. 1987. Blood
        Reviews 1: 169-76</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">16.&nbsp;&nbsp;&nbsp; Angastiniotis MA, Kyriakidou S,
        Hadjiminas M. 1986. How thalassaemia was controlled in Cyprus. World Health Forum 7:
        291-297.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">17.&nbsp;&nbsp;&nbsp; Modell B, Harris R, Lane B, Khan M,
        Darlison M, Petrou M, Old J, Layton M, Varnavides L. 2000. Informed choice in genetic
        screening for thalassaemia during pregnancy: audit from a national confidential enquiry.
        British Medical Journal 320: 325-390.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">18.&nbsp;&nbsp;&nbsp; WHO 1989.&nbsp; Glucose-6-Phosphate
        Dehydrogenase Deficiency. Report of a WHO Working Group. Bulletin of the World Health
        Organization 67: 601-611.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">19.&nbsp;&nbsp;&nbsp; Kromberg JGR, Castle D, Zwane EM,
        Jenkins T.&nbsp; Albinism and skin cancer in southern Africa.&nbsp; Clinical Genetics,
        1989.&nbsp; 36 :&nbsp; 43 - 52.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">20.&nbsp;&nbsp;&nbsp; Modell B, Kuliev AM. 1989.&nbsp; The
        impact of public health on human genetics.&nbsp; Clinical Genetics 36: 286-298</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">21.&nbsp;&nbsp;&nbsp; Barker DJP (ed). Fetal and infant
        origins of adult disease. British Medical Journal, Tavistock Square, London WC1H 9JR.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">22.&nbsp;&nbsp;&nbsp; Lumley J, Watson L, Watson M, Bower C.
        Periconceptional supplementation with folate and/or multivitamins for preventing neural
        tube defects (Cochrane Review). In: The Cochrane Library, Issue 4, 1999. Oxford: Update
        Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">23.&nbsp;&nbsp;&nbsp; Kramer MS. Balanced protein/energy
        supplementation in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 1999.
        Oxford: Update Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">24.&nbsp;&nbsp;&nbsp; Shangzhi Huang. Genetic Epidemiology
        Studies in China. Working paper prepared for this meeting.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">25.&nbsp;&nbsp;&nbsp; Ubbink JB, Christianson AL, Bester ML,
        Van Allen MI, Venter PA, &nbsp; Delport R, Blom HJ, van der Merwe A, Potgieter H, Vermaak
        WJH. Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase
        genotype in rural South African Blacks with a history of pregnancy complicated by neural
        tube defects. 1999. Metabolism 48 (2): 269-274.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">26.&nbsp;&nbsp;&nbsp; Pharoah PO. 1993. Iodine-supplementation
        trials. American Journal of Clinical Nutrition 57 (supplement) 276S-279S.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">27.&nbsp;&nbsp;&nbsp; Hercberg S, Galan P. 1992. Nutritional
        anaemias. Baillieres Clinical Haematology 5: 143-68</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">28.&nbsp;&nbsp;&nbsp; Walter T. 1994. Effect of
        iron-deficiency anaemia on cognitive skills in infancy and childhood. Baillieres Clinical
        Haematology 7(4): 815-27.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">29.&nbsp;&nbsp;&nbsp; Cook JD, Skikne BS, Baynes RD. 1994.
        Iron deficiency: the global perspective. Advances in Experimental Medicine and Biology
        356: 219-28.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">30.&nbsp;&nbsp;&nbsp; Mahomed K. Iron supplementation in
        pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 1999. Oxford: Update
        Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">31.&nbsp;&nbsp;&nbsp; Vitez M, Koranyi G, Goncy E, Rudas T,
        Czeizel A. 1984. A semiquantitative score system for epidemiologic studies of fetal
        alcohol syndrome. American Journal of Epidemiology 119: 301-308.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">32.&nbsp;&nbsp;&nbsp; Viljoen DL. Fetal alcohol syndrome
        (editorial) South African Medical Journal 1999. 89: 958 - 959.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">33.&nbsp;&nbsp;&nbsp; DiFranza JR, Lew RA. 1995. Effect of
        maternal cigarette smoking on pregnancy complications and sudden infant death syndrome.
        Journal of Family Practice 40: 385-94 </span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">34.&nbsp;&nbsp;&nbsp; Olofsson P, Liedholm H, Sartor G,
        Sjoberg N-O, Svennigsen NW, Ursing D. Diabetes in pregnancy. A 21 year Swedish material.
        Acta Obstetrica Gynaecologica Scandinavica 122&nbsp; (supplement): 1-62. 1984</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">35.&nbsp;&nbsp;&nbsp; Ylinen K, Aula P, Stenman U-H. 1984.
        Risk of minor and major malformations in diabetes with high haemoglobin A1c values in
        early pregnancy. British Medical Journal 289: 345-6.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">36.&nbsp;&nbsp;&nbsp; Samren EB, van Duijn CM; Christiaens GC;
        Hofman A; Lindhout D. 1999. Antiepileptic drug regimens and major congenital abnormalities
        in the offspring. Annals of Neurology 46: 739-46.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">37.&nbsp;&nbsp;&nbsp; Phillips-Howard P A, Wood D. 1996. The
        safety of antimalarial drugs in pregnancy. Drug Safety 14(3): pp.131-145.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">38.&nbsp;&nbsp;&nbsp; Adams S. 1996. Caring for the pregnant
        woman with sickle cell crisis. Professional Care of Mother and Child 6: 34-6.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">39.&nbsp;&nbsp;&nbsp; Afifi AM. 1974. High transfusion regime
        in the management of reproductive wastage and maternal complications of pregnancy in
        thalassaemia major. Acta Haematologica 52: 331-335.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">40.&nbsp;&nbsp;&nbsp; Drogari E, Smith I, Beasley M, Lloyd JK.
        Timing of strict diet in relation to fetal damage in maternal phenylketonuria. The Lancet
        ii, 927-930. 1987.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">41.&nbsp;&nbsp;&nbsp; Newell ML, Peckham C. Risk factors for
        vertical transmission of HIV-1 and early markers of HIV-1 infection in children. AIDS
        1993;7(Suppl 1):S91-7.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">42.&nbsp;&nbsp;&nbsp; Brocklehurst P. Interventions aimed at
        decreasing the risk of mother-to-child transmission of HIV infection (Cochrane Review).
        In: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">43.&nbsp;&nbsp;&nbsp; Clarke C, Whitfield AGW. 1984. Deaths
        from rhesus haemolytic disease in England and Wales during 1980 and 1981 and a comparison
        with earlier years. Journal of Obstetrics and Gynaecology 4: 218-222.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">44.&nbsp;&nbsp;&nbsp; Peyron F, Wallon M, Liou C, Garner P.
        Treatments for toxoplasmosis in pregnancy (Cochrane Review). In: The Cochrane Library,
        Issue 4, 1999. Oxford: Update Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">45.&nbsp;&nbsp;&nbsp; Wilson JMC, Jungner G. 1968. Principles
        and practice of screening for disease. Public Health Papers WHO No 34.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">46.&nbsp;&nbsp;&nbsp; Cuckle HS, Wald NJ. Principles of
        screening. In: Antenatal and neonatal screening, NJ Wald (ed). Oxford University Press,
        Oxford, New York and Toronto. 1984</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">47.&nbsp;&nbsp;&nbsp; Chitty L. Ultrasound screening for fetal
        abnormalities. In CH Rodeck and MJ Whittle (eds): Fetal Medicine. Basic science and
        clinical practice. Churchill Livingstone, London. 1999.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">48.&nbsp;&nbsp;&nbsp; Blaas HG, Eik-Nes. First trimester
        diagnosis of fetal malformations. In CH Rodeck and MJ Whittle (eds): Fetal Medicine. Basic
        science and clinical practice. Churchill Livingstone, London. 1999.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">49.&nbsp;&nbsp;&nbsp; Nicolaides KH, Souka AP, Noble PL. Fetal
        nuchal translucency at 10-14 weeks of gestation. In CH Rodeck and MJ Whittle (eds): Fetal
        Medicine. Basic science and clinical practice. Churchill Livingstone, London. 1999.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">50.&nbsp;&nbsp;&nbsp; Baayou Z. 1998. Non-invasive perinatal
        post mortem examination. M Phil thesis. University College London.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">51.&nbsp;&nbsp;&nbsp; Murray J, Cuckle H, Taylor G, Littlewood
        J, Hewison J. 1999. Screening for cystic fibrosis. Health Technology Assessment 3: No 8.
        (Full text available at www.hta.nhsweb.nhs.uk)</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">52.&nbsp;&nbsp;&nbsp; Kronn D, Jansen V, Ostrer H. 1998.
        Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the
        Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center,
        New York, NY. Archives of Internal Medicine 158: 777-81.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">53.&nbsp;&nbsp;&nbsp; Petrou M, Brugiatelli M, Ward RHT,
        Modell B. 1992. Factors affecting the uptake of prenatal diagnosis for sickle cell
        disease. Journal of Medical Genetics 29: 820-3.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">54.&nbsp;&nbsp;&nbsp; Serjeant GR. Sickle cell disease. Oxford
        University Press. Oxford, New York, Tokyo. 2nd edition 1992.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">55.&nbsp;&nbsp;&nbsp; Rajab A, Patton MA 1999. Analysis of the
        population structure Oman. Community Genetics 2: 23-26. </span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">56.&nbsp;&nbsp;&nbsp; Ahmed S, Saleem M, Sultana N, Raashid A,
        Waqar A, Anwar M, Modell B, Karamat KA, Petrou M. 2000. Prenatal diagnosis of beta
        thalassaemia in Pakistan: experience in a Muslim country. Prenatal Diagnosis 20: 378-383.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">57.&nbsp;&nbsp;&nbsp; Crowther CA, Keirse MJNC. Anti-D
        administration in pregnancy for preventing Rhesus alloimmunisation (Cochrane Review). In:
        The Cochrane Library, Issue 4, 1999. Oxford: Update Software.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">58.&nbsp;&nbsp;&nbsp; Luzzato L, Mehta A. Glucose-6-phosphate
        dehydrogenase deficiency. In Scriver CR, Beaudet AL, Sly WS, Valle D. (Eds). The metabolic
        basis of inherited disease. 6th edition. McGraw Hill Inc, New York. 1989.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">59.&nbsp;&nbsp;&nbsp; Davis A, Bamford J, Wilson I, Ramkalawan
        T, Forshaw M, Wright S. A critical review of the role of neonatal hearing screening in the
        detection of congenital hearing impairment. Health Technology Assessment 1997. 1: 10.
        (Full text available at www.hta.nhsweb.nhs.uk)</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">60.&nbsp;&nbsp;&nbsp; Ozand T, Devol EB, Generoso GG. 1992.
        Neurometabolic diseases at a national referral centre: five years experience in the King
        Faisal Specialist Hospital and Research Centre. Journal of Child Neurology 7: Supplement.
        S4 - S9.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">61.&nbsp;&nbsp;&nbsp; Seymour CA, Thomason MI, Chalmers RA,
        Addison GM, Bain MD, Cockburn E et al. Newborn screening for inborn errors of metabolism:
        a systematic review. Health Technology Assessment 1997: 1 (11).</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">62.&nbsp;&nbsp;&nbsp; WHO 1996.&nbsp; Report of a WHO
        Scientific Group.&nbsp; Control of hereditary diseases.&nbsp; WHO Technical Report Series
        865, Geneva:&nbsp; 1-86.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">63.&nbsp;&nbsp;&nbsp; WHO 1999.&nbsp; Services for the
        prevention and management of genetic diseases and birth defects in developing
        countries.&nbsp; Report of a WHO meeting (WHO/HGN/GL/WAOPBD/99.1):&nbsp; 1-100.</span></font></p>
        <p align="left"
        style="margin-left:20.25pt;text-align:left;
text-indent:-20.25pt;mso-list:l14 level1 lfo37;tab-stops:-72.0pt -36.0pt list 20.25pt"><font
        size="3"><span lang="EN-US">64.&nbsp;&nbsp;&nbsp; UN 1994.&nbsp; The standard rules on the
        equalization of opportunities for persons with disabilities:&nbsp; 1-41.</span></font></p>
        <span lang="EN-US"><p><strong><font size="3"><a name="Annex 1">Annex 1</a><br>
        Prevalence of genetic and congenital disorders in populations of European origin, to age
        12 (Ref. 2)</font></strong></span></p>
        <table border="1" width="94%">
          <tr>
            <td width="11%" rowspan="2"><font size="2"><span lang="EN-US">Category</span></font></td>
            <td width="12%" rowspan="2"><font size="2"><span lang="EN-US">Sub-group<o:p></o:p></span></font></td>
            <td width="57%" rowspan="2"><font size="2"><span lang="EN-US">Examples of common diagnoses<o:p></o:p></span></font></td>
            <td width="24%" colspan="2"><font size="2"><span lang="EN-US">Estimated births/1000<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="13%"><font size="2"><span lang="EN-US">sub-group<o:p></o:p></span></font></td>
            <td width="11%"><font size="2"><span lang="EN-US">category<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%"><font size="2"><span lang="EN-US">dominant<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Familial hypercholesterolaemia, adult
            polycystic kidney disease, neurofibromatosis, Huntington disease, achondroplasia<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">7<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Inherited (single gene) disorders<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">X-linked <o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Fragile X mental retardation, Duchenne
            muscular dystrophy, haemophilia A &amp; B, colour vision disorders<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.33<o:p></o:p></span></font></td>
            <td width="11%"><font size="2"><span lang="EN-US">10.0<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%"><font size="2"><span lang="EN-US">Recessive<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Glutathione deficiency, cystic fibrosis,
            alpha-1 antitrypsin deficiency, phenylketonuria, Werdnig-Hoffman disease, haemoglobin
            disorders<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.66</span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Chromosomal disorders<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">Autosomes<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Down syndrome <o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.7<o:p></o:p></span></font></td>
            <td width="11%"><font size="2"><span lang="EN-US">3.5<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%"><font size="2"><span lang="EN-US">Sex chromosomes<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Kleinfelter &amp; Turner syndrome<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.8<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Congen. malformations<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">Inherited<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Multiple malformation syndromes,
            polydactyly etc<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">0.6<o:p></o:p></span></font></td>
            <td width="11%"><font size="2"><span lang="EN-US">0.6<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Neural tube defect<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1 - 6<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Congenital heart disease<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">7 - 10<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Congen. malformations<o:p></o:p></span></font></td>
            <td width="12%"><font size="2"><span lang="EN-US">Multifactorial<o:p></o:p></span></font></td>
            <td width="57%"><font size="2"><span lang="EN-US">Talipes equinovarus<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.5<o:p></o:p></span></font></td>
            <td width="11%"><font size="2"><span lang="EN-US">30.0<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Congenital dislocation of hip<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">0.1 - 14<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Pyloric stenosis<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.5<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Cleft lip +/- palate<o:p></o:p></span></font></td>
            <td width="13%"><font size="2"><span lang="EN-US">1.0<o:p></o:p></span></font></td>
            <td width="11%">&nbsp;</td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Multifactorial disorders<o:p></o:p></span></font></td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Epilepsy, diabetes mellitus, obesity<o:p></o:p></span></font></td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">10.6<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">Genetic, type unknown<o:p></o:p></span></font></td>
            <td width="12%">&nbsp;</td>
            <td width="57%">&nbsp;</td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">1.2<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">TOTAL GENETIC <o:p></o:p></span></font></td>
            <td width="12%">&nbsp;</td>
            <td width="57%">&nbsp;</td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">55.9<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">No genetic component<o:p></o:p></span></font></td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Terminal transverse limb deficiency<o:p></o:p></span></font></td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">0.1<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%">&nbsp;</td>
            <td width="12%">&nbsp;</td>
            <td width="57%"><font size="2"><span lang="EN-US">Fetal rubella syndrome, fetal alcohol
            syndrome<o:p></o:p></span></font></td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">0.6<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="11%"><font size="2"><span lang="EN-US">TOTAL</span></font></td>
            <td width="12%">&nbsp;</td>
            <td width="57%">&nbsp;</td>
            <td width="13%">&nbsp;</td>
            <td width="11%"><font size="2"><span lang="EN-US">56.6<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt"><span lang="EN-US"><font size="2">&nbsp;</font><strong><font
        size="3"><a name="Annex 2">Annex 2<br>
        </a>Options for best possible care for common congenital disorders and birth defects (Ref.
        63)</font></strong></span></p>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt">&nbsp;</p>
        <table border="1" width="94%">
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Condition<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Diagnosis<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Specific complications<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Investigations<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Therapeutic intervention<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Spina bifida<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, newborn examination<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Spinal lesion, hydrocephalus,
            developmental delay, paraplegia, incontinence<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Brain scan, developmental<a
            style="mso-footnote-id:
  ftn1" href="#_ftn1" name="_ftnref1" title>*</a>/ psychometric
            assesment, urological evaluation<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Surgery, palliative care, NDT*prevention
            of urinary tract infections*, self catheterisation*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Cleft lip/ Palate<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, newborn examination<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Feeding problems, speech problems<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Audiological/ speech evaluation<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Surgery, buccal plate, NDT*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Talipes Equinovarus<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, newborn examination </span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Abnormal foot position<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">X-rays*<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Manipulation*, plaster of Paris*,
            surgery<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Undescended testes<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, newborn examination<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Sub-fertility, testicular cancer<o:p></o:p></span></font></td>
            <td width="20%">&nbsp;</td>
            <td width="20%"><font size="2"><span lang="EN-US">Surgery<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Congenital hypothyroidism<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Neonatal screening*, clinical, thyroid
            function tests<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Growth deficiency, mental retardation,
            umbilical hernia<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Growth monitoring* developmental* /
            psychometric assessment<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Thyroxine*, NDT*, surgery<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Achondroplasia<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, newborn examination, confirm
            by DNA<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Short stature, spinal gibbus, spinal
            cord compression, hydrocephalus, obstructed labour<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">DNA, X-rays*, brain scan<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Counselling on spinal posture*, surgery,
            Caesarian section*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Neurofibromatosis<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, confirm by DNA<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Tumors, plexiform neurofibroma, optic
            glioma, seizures, learning disability, long bone bowing<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">X-rays*, opthalmological assessment,
            EEG, developmental* / psychometric assessment<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Surgery, anticonvulsant therapy*, NDT*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Haemochromatosis<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, serum iron or ferritin,
            confirm by DNA<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Iron overload, cirrhosis, diabetes,
            cardiac failure, arthritis, liver cancer<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Liver function tests, glucose tolerance
            test, ECG* / X-rays* / ultrasound / angiogram<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Venesection*, diet* / Insulin* /
            diabetic medications*, cardiac failure therapy*, anti-inflammatories*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Fragile X-syndrome<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, confirm by DNA<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Mental retardation, behavioural problems<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Developmental* / psychometric assessment<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">NDT*, behavioural management*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Haemophilia A<o:p></o:p></span></font></td>
            <td width="17%"><font size="2"><span lang="EN-US">Clinical, confirm by clotting studies
            and DNA<o:p></o:p></span></font></td>
            <td width="23%"><font size="2"><span lang="EN-US">Bleeding diathesis, joint arthroses<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">PI / PTT, Factor VIII assay, X-rays*<o:p></o:p></span></font></td>
            <td width="20%"><font size="2"><span lang="EN-US">Factor VIII replacement*, physiotherapy*
            / surgery<o:p></o:p></span></font></td>
          </tr>
        </table>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt"><font size="2"><span lang="EN-US"><a
        style="mso-footnote-id:ftn1" href="#_ftnref1" name="_ftn1" title>*</a> Can be undertaken
        at primary health care level.</span></font></p>
        <p>&nbsp;</p>
        <p><strong><font size="3"><span lang="EN-US"><a name="Annex 2 (Continued)">Annex 2
        (Continued)</a><br>
        Options for best possible care in common congenital disorders and birth defects </span></font></strong></p>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt">&nbsp;</p>
        <table border="1" width="95%">
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Condition</span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Diagnosis<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Specific complications<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Investigations<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Therapeutic intervention<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Thalassemia<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical, blood film, Hb F estimation<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Chronic anaemia, hypersplenism, iron
            overload<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Hb level, annual blood consumption,
            ferritin<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Blood transfusion*,&nbsp; folic acid*,
            splenectomy, desferrioxamine*, deferiprone*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Sickle cell disorders<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical, blood film, Hb
            electrophoresis, sickle test<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Chronic anaemia, susceptibility to
            overwhelming infection, painful crises<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Regular review, <o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Information for parents*, protective
            precautions*, prophylactic antibiotics and antimalarials*,&nbsp; treatment of acute
            complications<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Oculo-cutaneous albinism<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical, newborn examination<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Skin lesions, nystagmus, visual
            problems, skin cancer<o:p></o:p></span></font></td>
            <td width="18%">&nbsp;</td>
            <td width="22%"><font size="2"><span lang="EN-US">Advice, sunscreen, glasses<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Trisomy 18 syndrome<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical, newborn examination, confirm
            by chromosome studies<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Growth deficiency, congenital heart
            defect, early death<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Growth monitoring*<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Palliative care*<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Fetal alcohol syndrome</span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Growth deficiency, mental retardation,
            behavioural abnormalities, congenital cardiac defects<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Growth monitoring*, developmental* /
            psychometric assessment, psychological assessment, ECG* / x-rays* / ultrasound / angiogram<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">NDT*, neuro-behavioural therapy, cardiac
            failure therapy* / surgery<o:p></o:p></span></font></td>
          </tr>
          <tr>
            <td width="20%"><font size="2"><span lang="EN-US">Fetal rubella syndrome<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Clinical, confirm by Rubella virus IgM /
            IgG<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">Growth deficiency, microcephaly, mental
            retardation, visual defects,deafness, congenital heart defects<o:p></o:p></span></font></td>
            <td width="18%"><font size="2"><span lang="EN-US">Growth monitoring*, developmental* /
            psychometric assessment, opthalmological assessment, auditory / speech assessment, ECG* /
            X-rays* / ultrasound / angiogram<o:p></o:p></span></font></td>
            <td width="22%"><font size="2"><span lang="EN-US">NDT*, surgery, cataract removal /
            glasses, hearing aid, cardiac failure therapy* <o:p></o:p></span></font></td>
          </tr>
        </table>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt"><font size="3"><span lang="EN-US">For
        all conditions in the table, clinical diagnosis, genetic counselling and psycho-social
        support are possible at primary health care level.<o:p></o:p></span></font></p>
        <p style="margin-bottom:0cm;margin-bottom:.0001pt">&nbsp;</td>
      </tr>
</TBODY>
      <tr>
        <td colSpan="2" vAlign="top" width="654" height="0"><hr>
        <h5 align="center">| <a href="/">WHO Home</a> |<br>
        | <a href="../asthma/index.htm">Asthma</a> | <a href="../cancer/index.htm">Cancer</a> | <a
        href="../cvd/index.htm">Cardiovascular diseases</a> | <a href="../dia/index.htm">Diabetes</a>
        | <a href="index.htm">Human genetics</a> | <a href="../orh/index.htm">Oral health</a> | <a
        href="http://www5.who.int/tobacco/">Tobacco use</a> | <a href="../noma/index.htm">Noma</a>
        |<br>
        </h5>
        <h5 align="left"><font size="2">Contact us: <a href="mailto:ncdinfo@who.int">ncdinfo@who.int</a>
        .<br>
        Copyright </font><font size="1"><a class="Asmall"
        href="/home/copyright/index.en.html">© WHO/OMS, 2001</a> </font></h5>
        </td>
      </tr>
    </table>
    </center></div></td>
  </tr>
</TBODY>
</table>
<p>&nbsp;</p>
</body>
</html>

